Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2022 | May 06, 2022 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-39484 | |
Entity Registrant Name | METROMILE, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 84-4916134 | |
Entity Address, Address Line One | 425 Market Street #700 | |
Entity Address, City or Town | San Francisco | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94105 | |
City Area Code | 888 | |
Local Phone Number | 242-5204 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 130,419,773 | |
Current Fiscal Year End Date | --12-31 | |
Amendment Flag | false | |
Entity Central Index Key | 0001819035 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Entity Filer Category | Large Accelerated Filer | |
Common Stock | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common Stock | |
Trading Symbol | MILE | |
Security Exchange Name | NASDAQ | |
Warrant | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants | |
Trading Symbol | MILEW | |
Security Exchange Name | NASDAQ |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Investments | ||
Marketable securities - restricted (amortized cost of $67,613 and $62,741) | $ 67,149 | $ 62,625 |
Total investments | 67,149 | 62,625 |
Cash and cash equivalents | 84,339 | 120,940 |
Restricted cash and cash equivalents | 31,978 | 42,881 |
Receivables from Brokers-Dealers and Clearing Organizations | 6,551 | 0 |
Premiums receivable | 18,522 | 16,839 |
Reinsurance recoverable on paid loss | 2,694 | 0 |
Reinsurance recoverable on unpaid loss | 4,408 | 0 |
Prepaid reinsurance premium | 359 | 0 |
Prepaid expenses and other assets | 27,416 | 21,677 |
Deferred policy acquisition costs, net | 1,204 | 1,433 |
Telematics devices, improvements and equipment, net | 12,169 | 13,654 |
Website and software development costs, net | 21,971 | 25,866 |
Intangible assets | 7,500 | 7,500 |
Assets held for sale | 9,253 | 0 |
Total assets | 295,513 | 313,415 |
Liabilities | ||
Loss and loss adjustment expense reserves | 76,916 | 73,438 |
Ceded reinsurance premium payable | 8,798 | 0 |
Payable to carriers - premiums and LAE, net | 315 | 340 |
Unearned premium reserve | 16,924 | 15,726 |
Deferred revenue | 0 | 5,601 |
Accounts payable and accrued expenses | 8,421 | 10,820 |
Payable for securities | 0 | 422 |
Warrant liability | 1,025 | 1,156 |
Other liabilities | 19,319 | 19,524 |
Liabilities held for sale | 6,156 | 0 |
Total liabilities | 137,874 | 127,027 |
Commitments and contingencies (Note 8) | ||
Stockholders’ equity | ||
Common stock, $0.0001 par value; 640,000,000 shares authorized as of March 31, 2022, and December 31, 2021; 130,183,262 and 128,221,885 shares issued and outstanding as of March 31, 2022 and December 31, 2021. | 13 | 13 |
Accumulated paid-in capital | 775,443 | 769,525 |
Accumulated other comprehensive loss | (464) | (116) |
Accumulated deficit | (617,353) | (583,034) |
Total stockholders' equity | 157,639 | 186,388 |
Total liabilities, convertible preferred stock and stockholders’ equity | $ 295,513 | $ 313,415 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Stockholders’ equity | ||
Marketable securities, amortized cost | $ 67,613 | $ 62,741 |
Common stock par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 640,000,000 | 640,000,000 |
Common stock, shares issued (in shares) | 130,183,262 | 128,221,885 |
Common stock, shares outstanding (in shares) | 130,183,262 | 128,221,885 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Revenue | ||
Premiums earned, net | $ 19,165 | $ 1,125 |
Investment income | 45 | 36 |
Other revenue | 1,489 | 16,115 |
Total revenue | 20,699 | 17,276 |
Costs and expenses | ||
Losses and loss adjustment expenses | 22,060 | 12,263 |
Policy servicing expense and other | 5,283 | 4,443 |
Sales, marketing and other acquisition costs | 6,459 | 47,294 |
Research and development | 4,277 | 3,650 |
Amortization of capitalized software | 3,368 | 2,651 |
Other operating expenses | 13,702 | 8,589 |
Total costs and expenses | 55,149 | 78,890 |
Loss from operations | (34,450) | (61,614) |
Other expense | ||
Interest expense | 0 | 15,876 |
(Decrease) increase in fair value of stock warrant liability | (131) | 26,137 |
Total other expense | (131) | 42,013 |
Loss before taxes | (34,319) | (103,627) |
Income tax benefit | 0 | 0 |
Net loss | $ (34,319) | $ (103,627) |
Net loss per share, basic (in dollars per share) | $ (0.27) | $ (1.37) |
Net loss per share attributable to common stockholders - diluted (in dollars per share) | $ (0.27) | $ (1.37) |
Weighted-average shares used in computing basic net loss per share (in shares) | 128,715,031 | 75,791,557 |
Weighted-average shares used in computing diluted net loss per share (in shares) | 128,715,031 | 75,791,557 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (34,319) | $ (103,627) |
Unrealized net loss on marketable securities | (348) | (9) |
Total comprehensive loss | $ (34,667) | $ (103,636) |
CONSOLIDATED STATEMENTS OF CONV
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands | Total | Previously Reported | Revision of Prior Period, Adjustment | Common Stock | Common StockPreviously Reported | Common StockRevision of Prior Period, Adjustment | APIC | APICPreviously Reported | Note Receivable | Note ReceivablePreviously Reported | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive IncomePreviously Reported | Accumulated Deficit | Accumulated DeficitPreviously Reported |
Beginning balance (in shares) at Dec. 31, 2020 | 68,776,614 | 67,728,286 | 1,048,328 | |||||||||||
Beginning balance at Dec. 31, 2020 | $ 304,469 | $ 304,469 | ||||||||||||
Convertible Preferred Stock | ||||||||||||||
Exercise of convertible preferred stock warrants (in shares) | 3,974,655 | |||||||||||||
Exercise of convertible preferred stock warrants | $ 132,718 | |||||||||||||
Conversion of preferred stock to common (in shares) | (72,751,269) | |||||||||||||
Conversion of preferred stock to common | $ (437,187) | |||||||||||||
Ending balance (in shares) at Mar. 31, 2021 | 0 | |||||||||||||
Ending balance at Mar. 31, 2021 | $ 0 | |||||||||||||
Beginning balance (in shares) at Dec. 31, 2020 | 8,992,039 | 8,854,978 | 137,061 | |||||||||||
Beginning balance at Dec. 31, 2020 | (361,496) | $ (361,496) | $ 1 | $ 1 | $ 5,482 | $ 5,482 | $ (415) | $ (415) | $ 11 | $ 11 | $ (366,575) | $ (366,575) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||||
Stock-based compensation | 3,208 | 3,208 | ||||||||||||
Exercises and vested portion of common stock options (in shares) | 1,089,670 | |||||||||||||
Exercises and vested portion of stock options | 2,059 | 2,059 | ||||||||||||
Conversion of promissory note | 0 | (415) | 415 | |||||||||||
RSUs withheld for tax purposes | (422) | (422) | ||||||||||||
Unrealized net loss on marketable securities | (9) | (9) | ||||||||||||
Conversion of preferred stock to common (in shares) | 72,751,269 | |||||||||||||
Conversion of preferred stock to common | 437,194 | $ 7 | 437,187 | |||||||||||
Business Combination and PIPE financing (in shares) | 43,894,156 | |||||||||||||
Business Combination and PIPE financing | 290,957 | $ 4 | 290,953 | |||||||||||
Net loss | (103,627) | (103,627) | ||||||||||||
Ending balance (in shares) at Mar. 31, 2021 | 126,727,134 | |||||||||||||
Ending balance at Mar. 31, 2021 | $ 267,864 | $ 12 | 738,052 | 0 | 2 | (470,202) | ||||||||
Beginning balance (in shares) at Dec. 31, 2021 | 0 | |||||||||||||
Beginning balance at Dec. 31, 2021 | $ 0 | |||||||||||||
Ending balance (in shares) at Mar. 31, 2022 | 0 | |||||||||||||
Ending balance at Mar. 31, 2022 | $ 0 | |||||||||||||
Beginning balance (in shares) at Dec. 31, 2021 | 128,221,885 | |||||||||||||
Beginning balance at Dec. 31, 2021 | 186,388 | $ 13 | 769,525 | 0 | (116) | (583,034) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||||
401K match with MILE stock (in shares) | 110,364 | |||||||||||||
401K match with MILE stock | 553 | 553 | ||||||||||||
Stock-based compensation (in shares) | 1,851,013 | |||||||||||||
Stock-based compensation | 5,258 | 5,258 | ||||||||||||
Exercises and vested portion of stock options | 107 | 107 | ||||||||||||
Unrealized net loss on marketable securities | (348) | (348) | ||||||||||||
Net loss | (34,319) | (34,319) | ||||||||||||
Ending balance (in shares) at Mar. 31, 2022 | 130,183,262 | |||||||||||||
Ending balance at Mar. 31, 2022 | $ 157,639 | $ 13 | $ 775,443 | $ 0 | $ (464) | $ (617,353) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (34,319) | $ (103,627) |
Adjustments to reconcile net loss to cash used in operating activities: | ||
Depreciation and amortization | 5,255 | 4,023 |
Stock-based compensation | 5,258 | 3,208 |
Change in fair value of warrant liability | (131) | 26,137 |
Telematics devices unreturned | 244 | 265 |
Amortization of debt issuance costs | 0 | 11,695 |
Noncash interest and other expense | 638 | 3,752 |
Changes in operating assets and liabilities: | ||
Premiums receivable | (1,683) | (2,678) |
Reinsurance recoverable on paid loss | (2,694) | 5,707 |
Reinsurance recoverable on unpaid loss | (4,408) | 25,247 |
Prepaid reinsurance premium | (359) | 7,351 |
Prepaid expenses and other assets | (7,443) | (2,972) |
Deferred transaction costs | 0 | 3,581 |
Deferred policy acquisition costs, net | (54) | (1,437) |
Accounts payable and accrued expenses | (1,939) | 1,400 |
Ceded reinsurance premium payable | 8,798 | (15,765) |
Loss and loss adjustment expense reserves | 3,478 | 4,488 |
Payable to carriers - premiums and LAE, net | (25) | 47 |
Unearned premium reserve | 1,198 | 2,189 |
Deferred revenue | 305 | (649) |
Other liabilities | (100) | (1,325) |
Net cash used in operating activities | (27,981) | (29,363) |
Cash flows from investing activities: | ||
Purchases of telematics devices, improvements, and equipment | (12) | (126) |
Payments relating to capitalized website and software development costs | (5,188) | (1,551) |
Net change in payable/(receivable) for securities | (6,973) | 822 |
Purchase of securities | (11,970) | (4,211) |
Sales and maturities of marketable securities | 7,013 | 5,805 |
Net cash (used in) provided by investing activities | (17,130) | 739 |
Cash flow from financing activities: | ||
Proceeds from notes payable | 0 | 2,015 |
Payment on notes payable | 0 | (69,351) |
Proceeds from merger with INSU II, net of issuance costs | 0 | 336,469 |
Proceeds from exercise of common stock options and warrants | 0 | 4,349 |
Net cash provided by financing activities | 0 | 273,482 |
Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents including cash classified within assets held for sale | (45,111) | 244,858 |
Less: Net increase in cash classified within assets held for sale | 2,393 | 0 |
Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | (47,504) | 244,858 |
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 163,821 | 50,188 |
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | 116,317 | 295,046 |
Supplemental cash flow data: | ||
Cash paid for interest | 0 | 3,164 |
Non-cash investing and financing transactions: | ||
Transaction costs in accrued liabilities at period end | 0 | 2,598 |
Warrants assumed from Business Combination | 0 | 45,516 |
Net exercise of preferred stock warrants | 0 | 56,160 |
Net exercise of promissory note | 0 | 415 |
Capitalized website and software development costs included in accrued liabilities | 231 | 137 |
Capitalized stock-based compensation | 758 | 171 |
Reclassification of liability to equity for vesting of stock options | $ 107 | $ 284 |
Overview and Basis of Presentat
Overview and Basis of Presentation | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Overview and Basis of Presentation | Overview and Basis of Presentation Metromile, Inc. (together with its consolidated subsidiaries, the “Company”) formerly known as INSU Acquisition Corp. II (“INSU”), was incorporated in Delaware on October 11, 2018. INSU was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The registration statement for INSU’s initial public offering (“IPO”) was declared effective on September 2, 2020. On September 8, 2020 INSU consummated the IPO of 23,000,000 units (“Units”), and, with respect to the shares of Class A common stock, par value $0.0001 (the “Class A Common Stock”) included in the Units sold (the “Public Shares”), which included the full exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Units, at $10.00 per Unit, generating gross proceeds of $230.0 million. Simultaneously with the closing of the IPO, INSU consummated the sale of 540,000 units (the “Placement Units”), at a price of $10.00 per Placement Unit in a private placement to the sponsor and Cantor Fitzgerald & Co. (“Cantor”), generating gross proceeds of $5.4 million. Transaction costs amounted to $14.2 million, consisting of $4.0 million in cash underwriting fees, $9.8 million of deferred underwriting fees and $0.4 million of other offering costs. Following the closing of the IPO on September 8, 2020, $230.0 million ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Placement Units was placed in a trust account (the “Trust Enterprise Business Solutions Held for Sale As of March 31, 2022, the Company had committed to a plan to sell its Enterprise Business Solutions segment and as such the assets and liabilities have been classified as held for sale in the Company's consolidated balance sheets beginning with the period ended March 31, 2022. The business does not meet the criteria to be classified as a discontinued operation; therefore, the results are reflected within continuing operations on the consolidated statements of operations. For additional information related to the held for sale business, please see Note 16, Business Disposition. Acquisition of Metromile, Inc. by Lemonade, Inc. On November 8, 2021, the Company entered into an Agreement and Plan of Merger (the “Agreement”) with Lemonade, Inc., a Delaware corporation (“Lemonade”), Citrus Merger Sub A, Inc., a Delaware corporation and a wholly-owned subsidiary of Lemonade (“Acquisition Sub I”) and Citrus Merger Sub B, LLC, a Delaware limited liability company and wholly owned subsidiary of Lemonade (“Acquisition Sub II”), pursuant to which (i) Acquisition Sub I will merge with and into Metromile (the “First Merger” and the effective time of the First Merger, the “First Effective Time”), with Metromile continuing as the surviving entity (the “Initial Surviving Corporation”), and (ii) the Initial Surviving Corporation will merge with and into Acquisition Sub II (the “Second Merger”), with Acquisition Sub II continuing as the surviving entity as a wholly owned subsidiary of Lemonade (the First Merger, the Second Merger and the other transactions contemplated by the Agreement, collectively, the “Proposed Transaction”). The Proposed Transaction implies a fully diluted equity value of approximately $500 million, or an enterprise value of about $340 million net of unrestricted cash and cash equivalents as September 30, 2021. In accordance with the Agreement, at the First Effective Time, each share of our common stock issued and outstanding immediately prior to the First Effective Time will be converted into the right to receive 0.05263(the “Exchange Ratio”) validly issued, fully paid and non-assessable shares of common stock of Lemonade, par value $0.00001 per share (“Lemonade Common Stock”). The Proposed Transaction is conditioned on customary closing conditions, including receipt of applicable regulatory approvals, and is expected to close in the second quarter of 2022. The applicable waiting period for the Proposed Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired and on February 1, 2022, the Proposed Transaction was approved by our stockholders. For additional information related to the Proposed Transaction, please see Note 4, Business Combinations included in this Quarterly Report on Form 10-Q, the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, the Company's Current Report on Form 8-K filed with the SEC on November 9, 2021 as well as the proxy statement/prospectus filed with the SEC on December 29, 2021. Business Combination On February 9, 2021, the Company consummated a merger pursuant to that certain Agreement and Plan of Merger and Reorganization, dated November 24, 2020, and as amended on January 12, 2021 and February 8, 2021 (the “Merger Agreement”), by and among INSU, INSU II Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of INSU (“Merger Sub”) and MetroMile, Inc., a Delaware corporation (“Legacy Metromile”), pursuant to which, among other things, Merger Sub merged with and into Legacy Metromile, with Legacy Metromile surviving the merger as a wholly owned subsidiary of the Company (the “Merger,” and together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the closing of the Business Combination (the “Closing”), the Company changed its name to Metromile, Inc., and Legacy Metromile changed its name to Metromile Operating Company. Unless the context indicates otherwise, references to “INSU” refer to the historical operations of INSU prior to the Closing, and references to the “Company,” “Metromile” and “Metromile Operating Company” refer to the historical operations of Legacy Metromile and its consolidated subsidiaries prior to the Closing and the business of the combined company and its subsidiaries following the Closing. The Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States (“GAAP”). Under this method of accounting, INSU, who was the legal acquirer, is treated as the “acquired” company for financial reporting purposes and Metromile Operating Company is treated as the accounting acquirer. This determination was primarily based on the fact that Metromile Operating Company’s stockholders prior to the Merger have a majority of the voting power of the Company, Metromile Operating Company’s senior management now comprise substantially all of the senior management of the Company, the relative size of Metromile Operating Company compared to the Company, and that Metromile Operating Company’s operations comprise the ongoing operations of the Company. Accordingly, for accounting purposes, the Merger is treated as the equivalent of a capital transaction in which Metromile Operating Company issued stock for the net assets of INSU, which are stated at historical cost, with no goodwill or other intangible assets recorded, and Metromile Operating Company’s financial statements became those of the Company. Pursuant to the Amended and Restated Certificate of Incorporation of the Company, at the closing, each share of INSU’s Class B Common Stock, par value $0.0001 per share (the “Class B Common Stock”), converted into one share of INSU’s Class A Common Stock. After the Closing and following the effectiveness of the Second Amended and Restated Certificate of Incorporation of the Company, each share of Class A Common Stock was automatically reclassified, redesignated and changed into one validly issued, fully paid and non-assessable share of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), without any further action by the Company or any stockholder thereof. On February 9, 2021, a number of purchasers (each, a “Subscriber”) purchased from the Company an aggregate of 17,000,000 shares of Common Stock (the “PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $170.0 million, pursuant to separate subscription agreements (each, a “Subscription Agreement”) entered into effective as of November 24, 2020. Pursuant to the Subscription Agreements, the Company gave certain registration rights to the Subscribers with respect to the PIPE Shares. The sale of PIPE Shares was consummated concurrently with the Closing. Description of Business after the Business Combination The Company, through Metromile Operating Company and its wholly owned subsidiary, Metromile Insurance Services LLC (the “GA Subsidiary”), sells pay-per-mile auto insurance to consumers in eight states: California, Washington, Oregon, Illinois, Pennsylvania, Virginia, New Jersey, and Arizona. Metromile Operating Company has a wholly owned subsidiary, Metromile Insurance Company (the “Insurance Company”), which focuses on property and casualty insurance. In January 2019, Metromile Operating Company formed Metromile Enterprise Solutions, LLC (“Enterprise”), a wholly owned subsidiary, which focuses on selling its insurance solution technology to third party customers. The Insurance Company provides auto insurance to customers with premiums based on a flat rate plus an adjustable rate based on actual miles driven. To record miles driven, the GA Subsidiary may provide drivers with a telematics device, the Metromile Pulse, which plugs into a car’s on-board diagnostic system to capture mileage. The GA Subsidiary acts as a full-service insurance General Agent (“GA”). As a full-service GA, the subsidiary provides all policy pricing, binding, and servicing (payments and customer service) for the policyholders. Until late 2016, the GA Subsidiary underwriting carrier was National General Insurance (“NGI”) and its related carriers. The GA Subsidiary began transitioning NGI-issued policies upon renewal in late 2016 to the Insurance Company and has only a small number of policies with NGI as of March 31, 2022. Policies underwritten by the Insurance Company are binded by the GA as well as through a network of independent agents. NGI handles claims for the GA Subsidiary’s policies underwritten by NGI and its related carriers, for which it pays NGI a fee for the LAE. NGI bears the risk of loss under these policies. Accordingly, the Company has no exposure to claims that would require an accrual for those NGI-related losses. The Insurance Company bears risk of loss under all insurance policies it underwrites. The financial statements include reserves for future claims based on actuarial estimates for the Insurance Company. The Loss and LAE reserves as of March 31, 2022 (unaudited) and December 31, 2021 were $76.9 million and $73.4 million, respectively. Basis of Presentation The accompanying interim unaudited consolidated financial statements have been prepared in accordance GAAP and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). References to the Accounting Standard Codification (“ASC”) and Accounting Standard Updates (“ASU”) included hereinafter refer to the Accounting Standards Codification and Updates established by the Financial Accounting Standards Board (“FASB”) as the source of authoritative GAAP. The consolidated financial statements include the accounts of Metromile, Inc. and its subsidiaries, all of which are wholly owned. All intercompany accounts and transactions have been eliminated in consolidation. These unaudited consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 ("the Company’s 2021 Annual Report"). Liquidity and Capital Resources Consistent with 2021, the Company's liquidity and capital resources were not materially impacted by COVID-19 and related economic conditions during the first three months of 2022. While these impacts have moderated since the beginning of the pandemic, there remains a risk that previous disruptions could return or new issues emerge as time amidst the pandemic perpetuates. The Company will continue to monitor and proactively adapt to the changing conditions and effects of COVID-19, but given the continued uncertainty about the duration or magnitude of the pandemic, it is not possible to reliably estimate the impact on the Company's financial condition, operations, and workforce. Reclassifications Reclassifications have been made to the prior year balances to conform to the current year presentation. In particular, accounts receivable, and digital assets, net have been combined with prepaid expenses and other assets into a single line on the consolidated balance sheets and consolidated statements of cash flows. The reclassifications had no effect on stockholders’ deficit or net loss after taxes as previously reported. Unaudited Interim Financial Information The accompanying interim consolidated balance sheets as of March 31, 2022, the interim consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ (deficit) equity for the three months ended March 31, 2021 and 2022, and cash flows for the three months ended March 31, 2021 and 2022 are unaudited. These unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2022 and the Company’s consolidated results of operations for the three months ended March 31, 2021 and 2022, and cash flows for the three months ended March 31, 2021 and 2022. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to contingent assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the reporting period. The Company’s principal estimates include: unpaid losses and LAE reserves; the fair value of investments; the fair value of stock-based awards; the fair value of the warrant liability; premium refunds to policyholders; reinsurance recoverable on unpaid loss; and the valuation allowance for income taxes. Because of uncertainties associated with estimating the amounts, timing and likelihood of possible outcomes, actual results could differ materially from these estimates. There have been no material changes to our significant accounting policies from our audited consolidated financial statements included in the Company’s 2021 Annual Report except as set forth below: Discontinued Operations and Held for Sale A business is classified as held for sale when management having the authority to approve the action commits to a plan to sell the business, the sale is probable to occur during the next 12 months at a price that is reasonable in relation to its current fair value and certain other criteria are met. A business classified as held for sale is recorded at the lower of its carrying amount or estimated fair value less cost to sell. When the carrying amount of the business exceeds its estimated fair value less cost to sell, a loss is recognized and updated each reporting period as appropriate. The results of operations of business classified as held for sale are reported as discontinued operations if the disposal represents a strategic shift that will have a major effect on the entity’s operations and financial results. Adoption of Accounting Standards For information regarding accounting standards that the Company adopted during the periods presented, see Note 1 of notes to the consolidated financial statements in the Company’s 2021 Annual Report. Recently Issued Accounting Pronouncements Reference Rate Reform In March 2020, FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued. The standard is effective upon issuance through December 31, 2022 and may be applied at the beginning of the interim period that includes March 12, 2020 or any date thereafter. The Company is currently evaluating this new standard and the impact it will have on its consolidated financial statements. This standard may be elected and applied prospectively over time from March, 2020 through December 31, 2022 as reference rate reform activities occur. The Company is evaluating the method of adoption and impact of the standard on its consolidated financial statements and related disclosures. Government Assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The amendments should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company is currently evaluating the impact of these amendments on its consolidated financial statements. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Topic 820, Fair Value Measurements , defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Topic 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a description of the valuation methodologies used for instruments measured at fair value on a recurring basis and recognized in the accompanying Consolidated Balance Sheet, as well as the general classification of such instruments pursuant to the valuation hierarchy. Cash and Cash Equivalents The Company’s cash and cash equivalents are demand and money market accounts and other highly liquid investments with an original maturity of three months or less. Demand and money market accounts are at stated values. Fair values for other cash equivalents are classified as Level 1 and are based upon appropriate valuation methodology. Marketable Securities — Available-for-sale The Company classifies highly liquid money market funds, U.S. Treasury bonds and certificates of deposit within Level 1 of the fair value hierarchy because they are valued based on quoted market prices in active markets and upon models that take into consideration such market-based factors as recent sales, risk-free yield curves, and prices of similarly rated bonds. Commercial paper, corporate bonds, corporate debt securities, repurchase agreements, and asset backed securities are classified within Level 2 because they are valued using inputs other than quoted prices that are directly or indirectly observable in the market, including readily available pricing sources for the identical underlying security which may not be actively traded. The Company did not hold any securities classified within Level 3 as of March 31, 2022 (unaudited) and December 31, 2021. Assets measured on a recurring basis at fair value, primarily related to marketable securities, included in the consolidated balance sheets as of March 31, 2022 (unaudited) and December 31, 2021 are set forth below (in thousands): Fair Value Measurement at March 31, 2022 (unaudited) Level 1 Level 2 Level 3 Total Cash equivalents Money market accounts $ 79,039 $ — $ — $ 79,039 Total cash equivalents $ 79,039 $ — $ — $ 79,039 Restricted cash equivalents Money market accounts $ 14,662 $ — $ — $ 14,662 Certificates of deposits 3,031 — — 3,031 Total restricted cash equivalents $ 17,693 $ — $ — $ 17,693 Marketable securities - restricted Corporate debt securities $ — $ 2,738 $ — $ 2,738 U.S. treasury and agency securities 37,693 1,956 — 39,649 Commercial paper — 18,550 — 18,550 Asset backed securities — 6,212 — 6,212 Total marketable securities - restricted $ 37,693 $ 29,456 $ — $ 67,149 Fair Value Measurement at December 31, 2021 Level 1 Level 2 Level 3 Total Cash equivalents Money market accounts $ 113,402 $ — $ — $ 113,402 Total cash equivalents $ 113,402 $ — $ — $ 113,402 Restricted cash equivalents Money market accounts $ 19,569 $ — $ — $ 19,569 Certificates of deposits 3,331 — — 3,331 Total restricted cash equivalents $ 22,900 $ — $ — $ 22,900 Marketable securities - restricted Corporate debt securities $ — $ 2,545 $ — $ 2,545 U.S. treasury securities 33,295 1,986 — 35,281 Commercial paper — 16,081 — 16,081 Asset backed securities — 8,718 — 8,718 Total marketable securities - restricted $ 33,295 $ 29,330 $ — $ 62,625 Public and Private Warrants At the Closing, Metromile Operating Company acquired the net liabilities from INSU, including warrants exercisable for common stock. The Company estimated the fair value of warrants exercisable for common stock measured at fair value on a recurring basis at the respective dates using the public trading price, for the Public warrants, and the Black-Scholes option valuation model, for the Private placement warrants (together with the public warrants, the “Warrants”), respectively. The Black-Scholes option valuation model inputs are based on the estimated fair value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, the risk-free interest rates, the expected dividends, and the expected volatility of the price of the Company’s underlying stock. These estimates, especially the expected volatility, are highly judgmental and could differ materially in the future. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. The Company considers its Public warrants to be Level 1 liabilities as it uses publicly and readily available information to measure the fair value of the warrants. For the Company's Private placement warrants, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date and as such are classified as Level 2 liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 1, Level 2, and Level 3 liabilities for the year ended December 31, 2021 and the three months ended March 31, 2022 (unaudited) (in thousands): Balance at December 31, 2020 $ 83,652 Increase in fair value of warrants 47,062 Exercise of preferred stock warrants prior to Business Combination (130,714) Public and Private placement Warrants acquired in Business Combination 45,623 Decrease in fair value of Public and Private placement Warrants (44,467) Balance at December 31, 2021 $ 1,156 Decrease in fair value of warrants (131) Balance at March 31, 2022 $ 1,025 The fair value of the Private placement warrants was determined using the Black-Scholes option valuation model using the following assumptions for values as of March 31, 2022: Estimated Fair Value of Warrants as of March 31, Exercise Dividend Volatility Risk-Free Expected (in thousands) (in whole dollars) (in years) Private placement warrants $ 28.8 $ 11.50 0 % 75 % 2.44 % 3.86 In connection with the Merger, each of the Metromile Operating Company convertible preferred stock warrants outstanding as of December 31, 2020 was exercised for shares of Metromile Operating Company common stock. Therefore, there were no convertible preferred stock warrants outstanding after the Closing. Through the three months ended March 31, 2022 and 2021 (unaudited), there were no transfers to or from any Level. The carrying amounts of accounts payable, accrued expenses and notes payable approximate their fair values because of the relatively short periods until they mature or are required to be settled. |
Marketable Securities
Marketable Securities | 3 Months Ended |
Mar. 31, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Marketable Securities | Marketable Securities The Company has investments in certain debt securities that have been classified as available-for-sale and recorded at fair value. These investments are included in both assets for securities with a maturity of one-year or less and assets for securities with a maturity of more than one-year. These securities are held in the Insurance Company and shown as restricted given that the transfer of these assets is subject to the approval of the state regulators. As of March 31, 2022 (unaudited) and December 31, 2021, deposits with various states consisted of bonds, cash and cash equivalents with carrying values of $5.2 million in both periods. Following the adoption of accounting guidance for credit losses on January 1, 2021, when marketable securities are in an unrealized loss position and the Company does not record an intent-to-sell impairment, the Company will record an allowance for credit losses ("ACL") for the portion of the unrealized loss due to a credit loss. Any remaining unrealized loss on a fixed maturity after recording an ACL is the non-credit amount and is recorded in other comprehensive income (loss) ("OCI"). The ACL is the excess of the amortized cost over the greater of the Company's best estimate of the present value of expected future cash flows or the security's fair value. The ACL cannot exceed the unrealized loss and, therefore, it may fluctuate with changes in the fair value of the fixed maturity if the fair value is greater than the Company's best estimate of the present value of expected future cash flows. The initial ACL and any subsequent changes are recorded in net realized capital gains and losses. The ACL is written off against the amortized cost in the period in which all or a portion of the related fixed maturity is determined to be uncollectible. For further information refer to Note 1, Basis of Presentation and Significant Accounting Policies in the Company’s 2021 Annual Report. As of December 31, 2021 and March 31, 2022 (unaudited), the Company did not recognize credit losses. The amortized cost and fair value of investments in fixed maturities classified as available-for-sale as of March 31, 2022 (unaudited) and December 31, 2021 are presented below (in thousands): As of March 31, 2022 (Unaudited) Amortized ACL Unrealized Unrealized Estimated Marketable securities - restricted Corporate debt securities $ 2,741 $ — $ — $ (3) $ 2,738 U.S. treasury and agency securities 40,088 — — (439) 39,649 Commercial paper 18,550 — — — 18,550 Asset backed securities 6,234 — — (22) 6,212 Total marketable securities - restricted $ 67,613 $ — $ — $ (464) $ 67,149 As of December 31, 2021 Amortized ACL Unrealized Unrealized Estimated Marketable securities - restricted Corporate debt securities $ 2,547 $ — $ — $ (2) $ 2,545 U.S. treasury securities 35,385 — — (104) 35,281 Commercial paper 16,081 — — — 16,081 Asset backed securities 8,728 — — (10) 8,718 Total marketable securities - restricted $ 62,741 $ — $ — $ (116) $ 62,625 The amortized cost and estimated fair value of marketable securities as of March 31, 2022 (unaudited) and December 31, 2021 and are shown below by contractual maturity (in thousands): As of March 31, Amortized Estimated Due within one year $ 52,471 $ 52,298 Due between one to five years 15,142 14,851 $ 67,613 $ 67,149 As of December 31, Amortized Estimated Due within one year $ 41,603 $ 41,596 Due between one to five years 21,138 21,029 $ 62,741 $ 62,625 The following table summarizes, for all fixed maturities classified as available-for-sale in an unrealized loss position at March 31, 2022, the aggregate fair value and gross unrealized loss by length of time those securities have been continuously in an unrealized loss position. The fair value amounts reported in the tables are estimates that are prepared using the process described in Note 2, Fair Value. The Company also relies upon estimates of several factors in its review and evaluation of individual investments, using the process described in Note 1, Basis of Presentation and Significant Accounting Policies in the Company’s 2021 Annual Report in determining whether a credit loss impairment exists. As of March 31, 2022 (unaudited) Less Than 12 Months 12 Months or Longer Total Fair Value Unrealized Fair Value Unrealized Fair Value Unrealized Marketable securities - restricted Corporate debt securities $ 732 $ (3) $ — $ — $ 732 $ (3) U.S. treasury and agency securities 39,649 (439) — — 39,649 (439) Commercial paper 1,006 — — — 1,006 — Asset backed securities 6,212 (22) — — 6,212 (22) Total in an unrealized loss position $ 47,599 $ (464) $ — $ — $ 47,599 $ (464) As of December 31, 2021 Less Than 12 Months 12 Months or Longer Total Fair Value Unrealized Fair Value Unrealized Fair Value Unrealized Marketable securities - restricted Corporate debt securities $ 737 $ (2) $ — $ — $ 737 $ (2) U.S. treasury and agency securities 31,809 (104) — — 31,809 (104) Commercial paper 1,808 — — — 1,808 — Asset backed securities 8,716 (10) — — 8,716 (10) Total in an unrealized loss position $ 43,070 $ (116) $ — $ — $ 43,070 $ (116) |
Business Combination
Business Combination | 3 Months Ended |
Mar. 31, 2022 | |
Reverse Recapitalization [Abstract] | |
Business Combination | Business Combination INSU As described in Note 1, Basis of Presentation and Significant Accounting Policies, the Merger with INSU was consummated on February 9, 2021 (the “Closing Date”). For financial accounting and reporting purposes under GAAP, the Business Combination was accounted for as a reverse acquisition and recapitalization, with no goodwill or other intangible asset recorded. As a result, the historical operations of Metromile Operating Company are deemed to be those of the Company. Thus, the financial statements included in this report reflect (i) the historical operating results of Metromile Operating Company prior to the Business Combination; (ii) the combined results of the Company and Metromile Operating Company following the Business Combination; (iii) the assets and liabilities of Metromile Operating Company at their historical cost; and (iv) the Company’s equity structure for all periods presented. In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparative periods up to the Closing Date, to reflect the number of shares of the Company’s common stock issued to Metromile Operating Company stockholders in connection with the recapitalization transaction. As such, the shares and corresponding capital amounts and earnings per share related to Metromile Operating Company redeemable convertible preferred stock and Metromile Operating Company common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio established in the Merger Agreement. Activity within the statement of stockholder’s equity for the issuances and repurchases of Metromile Operating Company redeemable preferred stock, were also retroactively converted to Metromile Operating Company common stock. The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of stockholders’ equity for the three months ended March 31, 2021 (dollars in thousands). Recapitalization Cash – INSU’s trust and cash (net of redemptions) $ 229,925 Cash – PIPE 170,000 Less transaction costs and advisory fees paid 31,456 Less cash payments to Metromile Operating Company stockholders 32,000 Net Business Combination and PIPE financing 336,469 Less non-cash net liabilities assumed from INSU 45,516 Net contributions from Business Combination and PIPE Financing $ 290,953 Number of Shares INSU Class A Common stock, outstanding prior to Business Combination 23,540,000 INSU Class B Common stock, outstanding prior to Business Combination 6,669,667 Less redemption of INSU shares 8,372 Common stock of INSU 30,201,295 Shares issued in PIPE 17,000,000 Business Combination and PIPE financing shares 47,201,295 Metromile Operating Company shares (1) 79,525,839 Total shares of common stock immediately after Business Combination 126,727,134 (1) The number of Metromile Operating Company shares was determined from the 78,313,665 shares of Metromile Operating Company common and preferred stock outstanding immediately prior to the closing of the Business Combination, which are presented net of the common and preferred stock redeemed, converted at the Exchange Ratio of 1.01547844. All fractional shares were rounded down. Lemonade As described above in Note 1, Basis of Presentation and Significant Accounting Policies the Company and Lemonade have entered into the Agreement, pursuant to which Lemonade will acquire the Company in an all-stock transaction that implies a fully diluted equity value of approximately $500 million, as of November 5, 2021 which was the last full trading day prior to public announcement of the Proposed Transaction, or an enterprise value of about $340 million net of unrestricted cash and cash equivalents as of September 30, 2021. In accordance with the Agreement, at the First Effective Time, each share of the Company’s common stock issued and outstanding immediately prior to the First Effective Time will be converted into the right to receive 0.05263 (the “Exchange Ratio”) validly issued, fully paid and non-assessable shares of common stock of Lemonade, par value $0.00001 per share (“Lemonade Common Stock”). At the First Effective Time, (i) each Metromile stock option that is held by an individual who, as of November 8, 2021, was not employed or providing services to the Company or its subsidiaries shall be cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (A) the excess, if any, of the product of (1) the average of the volume weighted average trading prices per share of Lemonade common stock on NYSE on each of the 20 consecutive trading days ending on (and including) the trading day that is three trading days prior to the First Effective Time multiplied by the Exchange Ratio (the “Per Metromile Share Price”), over the (2) the per share exercise price of such Metromile stock option, multiplied by (B) the total number of shares subject to such Metromile stock option; (ii) each other Metromile stock option shall be assumed by Lemonade and automatically converted into a stock option to acquire number of shares of Lemonade common stock (rounded down to the nearest whole share) equal to the product of (A) the number of shares subject to the Metromile stock option and (B) the Exchange Ratio, with an exercise price per share of Lemonade common stock (rounded up to the nearest whole cent) equal to (1) the per share exercise price of the Metromile stock option divided by (2) the Exchange Ratio; (iii) each award of Metromile restricted stock units that (A) is held by any non-employee director of Metromile or (B) vests based on the achievement of one or more performance criteria shall be cancelled and converted automatically into the right to receive an amount in cash equal to the Per Metromile Share Price in respect of each share of common stock underlying such Metromile restricted stock units (in the case of performance-based Metromile restricted stock units, based on actual performance); (iv) each other award of Metromile restricted stock units shall be assumed by Lemonade and automatically converted into an award of Lemonade restricted stock units covering a number of shares of Lemonade common stock equal to (A) the number of shares of Metromile common stock underlying such Metromile restricted stock units multiplied by (B) the Exchange Ratio; and (v) each Metromile warrant exercisable for shares of the Company’s common stock shall be assumed by Lemonade and converted into a corresponding warrant denominated in shares of Lemonade Common Stock (with the number of warrants and exercise price being adjusted based on the Exchange Ratio). Except as otherwise set forth above, each Metromile stock option, restricted stock unit award, and warrant assumed by Lemonade shall continue to have the same terms and conditions as applied immediately prior to the First Effective Time. The consummation of the Proposed Transaction is subject to the satisfaction or waiver of certain closing conditions, some of which have been completed, including among others (i) the effectiveness of the registration statement on Form S-4 registering the shares of Lemonade Common Stock issuable in the Proposed Transaction and absence of any stop order or proceedings by the SEC with respect thereto; (ii) the adoption of the Agreement by holders of a majority of the outstanding shares of the Company’s common stock; (iii) the expiration or early termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iv) receipt of other material regulatory consents and approvals; (v) the approval for listing on the New York Stock Exchange of the shares of Lemonade Common Stock to be issued pursuant to the Agreement; (vi) the absence of governmental restraints or prohibitions preventing the consummation of the Proposed Transaction; (vii) subject to specified materiality standards, the truth and accuracy of the representations and warranties made by each party; (viii) the compliance with or performance by the other party in all material respects of the covenants in the Agreement; and (ix) the absence of a material adverse effect on each party. Upon the consummation of the Proposed Transaction, the Company will cease to be a publicly traded company. The Company has agreed to various customary covenants and agreements, including, among others, agreements to conduct business in the ordinary course during the period between the execution of the agreement and the effective time of the Proposed Transaction. The Company does not believe these restrictions will impact the Company’s ability to meet its ongoing costs of operations, working capital needs, or capital expenditure requirements. As of March 31, 2022 (unaudited), the Company has incurred $3.8 million in transaction costs, $0.3 million in the three months ended March 31, 2022 (unaudited) and the remainder in 2021, in connection with the Proposed Transaction. Transaction costs are expensed as incurred and included within Other operating expenses of the consolidated statements of operations. |
Deferred Policy Acquisition Cos
Deferred Policy Acquisition Costs, Net | 3 Months Ended |
Mar. 31, 2022 | |
Deferred Policy Acquisition Costs Disclosures [Abstract] | |
Deferred Policy Acquisition Costs, Net | Deferred Policy Acquisition Costs, Net Deferred policy acquisition costs, net ("DPAC") consists of the following (in thousands): March 31, December 31, (unaudited) Deferred policy acquisition costs $ 11,655 $ 11,533 Deferred ceding commission (181) (114) Accumulated amortization (10,270) (9,986) Deferred policy acquisition costs, net $ 1,204 $ 1,433 For the three months ended March 31, 2022 and 2021 (unaudited), total amortization expense was approximately $0.3 million and $0.4 million, respectively. During all periods presented the amortization expense was included as part of sales, marketing and other acquisition costs in the Company’s consolidated statements of operations. |
Loss and Loss Adjustment Expens
Loss and Loss Adjustment Expense Reserves | 3 Months Ended |
Mar. 31, 2022 | |
Insurance [Abstract] | |
Loss and Loss Adjustment Expense Reserves | Loss and Loss Adjustment Expense Reserves The following table provides a reconciliation of the beginning and ending reserve balances for losses and LAE, net of reinsurance recoverable, for the three months ended March 31, 2021 and 2022 (unaudited) (in thousands): Three Months Ended 2022 2021 (unaudited) Balance at January 1 $ 73,438 $ 57,093 Less reinsurance recoverable — (33,941) Net balance at January 1 73,438 23,152 Incurred related to: Current year 21,874 9,566 Prior years 96 2,664 Total incurred 21,970 12,230 Paid related to: Current year 8,035 695 Prior years 14,865 (18,200) Total paid 22,900 (17,505) Net balance at end of period 72,508 52,887 Plus reinsurance recoverable 4,408 8,694 Balance at end of period $ 76,916 $ 61,581 These reserve estimates are generally the result of ongoing analysis of recent loss development trends and emerging historical experience. Original estimates are increased or decreased as additional information becomes known regarding individual claims. In setting reserves, the Company reviewed its loss data to estimate expected loss development. Management believes that the use of sound actuarial methodology applied to its analyses of historical experience provides a reasonable estimate of future losses. However, actual future losses may differ from the Company’s estimates, and future events beyond the control of management, such as changes in law, judicial interpretations of law and inflation, may favorably or unfavorably impact the ultimate settlement of the Company’s losses and LAE. The anticipated effect of inflation is implicitly considered when estimating liabilities for losses and LAE. While anticipated price increases due to inflation are considered in estimating the ultimate claim costs, the increase in average severities of claims is caused by a number of factors that vary with the individual type of policy written. Future average severities are projected based on historical trends adjusted for implemented changes in underwriting standards, policy provisions, and general economic trends. The estimation of unpaid losses and LAE reserves is based on existing factors at the date of estimation. Accordingly, future events may result in ultimate losses and LAE significantly varying from a reasonable provision as of the date of estimation. Unfavorable development of claims in future years could result in a significant negative impact on operations, stockholders’ surplus, and risk-based capital. Such development, if not offset by other increases in stockholders’ surplus, could result in the insurance departments of the state of domicile taking regulatory actions against the Company. |
Reinsurance
Reinsurance | 3 Months Ended |
Mar. 31, 2022 | |
Reinsurance Disclosures [Abstract] | |
Reinsurance | Reinsurance During the periods presented, the Company used reinsurance contracts to protect itself from losses due to concentration of risk and to manage its operating leverage ratios. As of December 31, 2021, the Company had commuted all of its reinsurance agreements. For further discussion of the reinsurance agreements in place as of March 31, 2021, see Note 10, Reinsurance of Notes to Consolidated Financial Statements included in the Company’s 2021 Form 10-K Annual Report. Effective January 1, 2022, the Company entered into an agreement with Swiss Reinsurance America Corporation ("Swiss Re") and Mapfre Re, Compania de Reaseguros, S.A ("Mapfre"). On a prospective basis, under the terms of the transaction, 30% of the Company's gross written premiums, losses, and certain LAE expenses are ceded to the reinsurers through June 30, 2023. The insurance company was not relieved of its primary obligations to policyholders as a result of any reinsurance agreements. Failure of reinsurers to honor their obligations could result in losses to the Company. The credit risk associated with the Company’s reinsurance contracts was mitigated by carefully selecting its reinsurers and monitoring their financial strength ratings. The 2022 reinsurance counterparties and their A.M. Best financial strength ratings are as follows: Swiss Re (A+) and, Mapfre (A). Reinsurance recoverables are presented on the consolidated balance sheets net of the allowance for estimated uncollectible reinsurance (“ACL”), if any. As of March 31, 2022, no ACL is required on these balances. The Company estimates the ACL based on the amount of reinsurance recoverables exposed to loss multiplied by estimated factors for the probability of default and the amount of loss given default. The probability of default is assigned based on each reinsurer's credit rating. Of the total reinsurance recoverables at March 31, 2022, all were rated by A.M. Best Company. Credit ratings are reviewed on a quarterly basis and any significant changes are reflected in an updated estimate. The loss given default factors are based on a study of historical recovery rates for general creditors as estimated through multiple economic cycles. The effect of the Company’s reinsurance agreements on premiums, loss and LAE related to the insurance company for the three months ended March 31, 2022 (unaudited) and the year ended December 31, 2021 is as follows (in thousands): March 31, 2022 (unaudited) Premium Premium Unearned Losses and LAE Loss and LAE Direct $ 29,328 $ 28,131 $ 16,924 $ 29,072 $ 76,916 Ceded (8,798) (8,440) (359) (7,102) (4,408) Net $ 20,530 $ 19,691 $ 16,565 $ 21,970 $ 72,508 December 31, 2021 Premium Premium Unearned Losses and LAE Loss and LAE Direct $ 110,719 $ 111,063 $ 15,726 $ 102,991 $ 73,438 Ceded (19,411) (33,080) — (14,701) — Net $ 91,308 $ 77,983 $ 15,726 $ 88,290 $ 73,438 |
Leases, Commitments, and Contin
Leases, Commitments, and Contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Leases, Commitments, and Contingencies | Leases, Commitments, and Contingencies Leases Metromile has non-cancellable and cancellable operating lease agreements for two real estate locations in Tempe, Arizona and its corporate headquarters in San Francisco, California with various expiration dates through 2030. The right-of-use asset as of March 31, 2022 (unaudited) was $13.8 million and is included in Prepaid expenses and other assets Other liabilities Litigation Shareholder Matters The Company and/or its current and/or former directors and/or executive officers are named as defendants in a number of lawsuits initiated by putative holders of Metromile, Inc. common stock. Following the Agreement and announcement thereof, multiple complaints were filed against the Company and certain current and former officers and directors alleging that the Company’s disclosures concerning the Lemonade transaction were incomplete. The Company also received demands to inspect its books and records under Delaware General Corporation Law Section 220, and one stockholder commenced litigation to enforce inspection rights. All of the foregoing complaints have been voluntarily dismissed as moot, with the plaintiffs reserving their rights to seek a fee in connection with each respective litigation. At this time an estimate of the probable loss or range of loss cannot be made. |
Stockholders_ Equity
Stockholders’ Equity | 3 Months Ended |
Mar. 31, 2022 | |
Stockholders' Equity Note [Abstract] | |
Stockholders’ Equity | Stockholders’ Equity Common Stock As of March 31, 2022 (unaudited), the Company had authorized a total of 640,000,000 shares for issuance as common stock. As of March 31, 2022 (unaudited), the Company had 130,183,262 shares of common stock issued and outstanding. Preferred Stock As of March 31, 2022 (unaudited), the Company had authorized a total of 10,000,000 shares for issuance as preferred stock. The Company’s board of directors has the authority to issue preferred stock and to determine the rights, privileges, preferences, restrictions, and voting rights of those shares. As of March 31, 2022, the Company had no shares of preferred stock outstanding. |
Public and Private Warrants
Public and Private Warrants | 3 Months Ended |
Mar. 31, 2022 | |
Public And Private Warrants [Abstract] | |
Public and Private Warrants | Public and Private WarrantsAs of March 31, 2022 (unaudited), the Company had 7,666,646 public warrants and 180,000 private placement warrants outstanding. Each whole warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment, at any time commencing on September 8, 2021, which was the later of 30 days after the completion of the Business Combination or 12 months from INSU’s IPO closing date. The public warrants will expire on the fifth anniversary of the Business Combination, or earlier upon redemption or liquidation. The Company may call the public warrants for redemption: • in whole or in part; • at a price of $0.01 per warrant; • Upon a minimum of 30 days’ prior written notice of redemption; and • if, and only if, the last reported closing price of the ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. If the Company calls the public warrants for redemption, management will have the option to require all holders that wish to exercise the public warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. |
Stock Option Plans
Stock Option Plans | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Stock Option Plans | Stock Option Plans Restricted Stock Units (“RSUs”) During the three months ended March 31, 2022 (unaudited), the Company granted 819,227 restricted stock units (“RSUs”) under the 2021 Plan which are conditional based on continued employment or service for a specified period. Compensation cost related to RSU grants is recognized on a straight-line basis over the vesting period and is calculated using the closing price per share of the Company's common stock on the grant date. For the three months ended March 31, 2022 (unaudited), the Company recorded compensation expense of $5.0 million related to non-performance based RSUs. A summary of the Company’s RSUs as of March 31, 2022 (unaudited) is presented in the table below: Number of RSUs Weighted-Average Fair Balance at December 31, 2021 7,241,980 $ 8.19 Granted 819,227 1.28 Vested (496,366) 10.15 Forfeited (620,551) 6.03 Balance at March 31, 2022 6,944,290 $ 7.43 As of March 31, 2022 (unaudited), there was $48.3 million of total unrecognized compensation cost related to RSUs. That cost is expected to be recognized over a weighted-average period of 2.55 years. The total grant date fair value of shares vested during the three months ended March 31, 2022 (unaudited) was $5.0 million. Performance Based Awards As of December 31, 2020, the Company had issued 150,000 outstanding performance-based awards (“PSUs”) to Dan Preston, Metromile’s Chief Executive Officer (“CEO”). As of the Closing, the performance-based provision was achieved for the outstanding performance-based awards as the Company completed a change in control event, and the Company recognized the expense related to these PSUs on the Closing date as there were no remaining vesting provisions. As a result, the Company recorded $2.5 million in stock-based compensation expense for the three months ended March 31, 2021 (unaudited). During 2021, the Company issued 2,216,870 PSUs, net of forfeitures, most of which each have a term of five years subject to continuous services by each holder. One third of PSUs that vest are based on a specific number of policies in force achieved by the Company. One third of the PSUs that vest are based on the Company achieving positive operating cash flow for a period of at least one financial quarter. One third of the PSUs vest based on a market condition of the Company achieving a specific price per share for at least 20 days in a 30-day trading window. Once the performance targets are met, the PSUs that relate to the specific performance target vest immediately. For the three months ended March 31, 2022 (unaudited), the Company had recorded $0.1 million in expense from the PSUs related to the market condition. None of the performance conditions were probable of being satisfied as of March 31, 2022 and, therefore, there is no unrecognized stock compensation related to PSUs. The Company did not grant any PSU's in the three months ended March 31, 2022 (unaudited). 2011 Stock Plan In 2011, the Company’s Board of Directors adopted the 2011 Equity Incentive Plan (the “2011 Plan”). The 2011 Plan provides for the granting of stock options to officers, directors, employees, and consultants of the Company. Options granted under the 2011 Plan may be Incentive Stock Options (“ISO”) or non-statutory Stock Options (“NSO”) as determined by the Board of Directors at the time of the option grant. The remaining unallocated shares reserved under the 2011 Plan were cancelled and no new awards will be granted under the 2011 Plan. Awards outstanding under the 2011 Plan were assumed by the Company upon the closing and continue to be governed by the terms of the 2011 Plan. 2021 Stock Plan In connection with the Closing, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”), under which 38,018,247 shares of common stock were initially reserved for issuance for ISOs. The 2021 Plan allows for the issuance of ISOs, NSOs, restricted stock awards, stock appreciation rights, restricted stock units (“RSUs”), and performance awards. The Board of Directors determines the period over which options become exercisable and options generally vest over a four-year period. The 2021 Plan became effective immediately following the closing. The Company uses the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or modification. The Company amortizes the estimated fair value to stock compensation expense using the straight-line method over the vesting period of the option. The following is a description of the significant assumptions used in the option pricing model: • Expected term — The expected term is the period of time when granted options are expected to be outstanding. In determining the expected term of options, the Company utilized the midpoint between the vesting date and contractual expiration date. • Volatility — Because the Company’s stock has limited trading history, the Company calculates volatility by using the historical stock prices of comparable public companies. • Risk-free interest rate — The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the rate of treasury securities with the same term as the options. • Forfeiture rate — The weighted average forfeiture rate of unvested options. • Expected dividends — The Company does not have plans to pay cash dividends in the future. Therefore, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. There were no options granted during the three months ended March 31, 2022 (unaudited). The following assumptions were used to estimate the value of options granted during the year ended December 31, 2021: Year ended December 31, Forfeiture rate 26.2 % Volatility 62.00 % Expected term (years) 5.33 Risk-free interest rate 0.53 % Expected dividends — Stock Option Activity The following table summarizes the activity of the Company’s stock option plan as of March 31, 2022 (unaudited): Stock Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 2,374,504 $ 3.00 8.25 $ 375 Options granted — $ — Options exercised — $ — Options cancelled or expired and returned to plan (717,331) $ 3.00 Outstanding as of March 31, 2022 1,657,173 $ 3.01 7.94 $ — Vested and exercisable to vest as of March 31, 2022 723,575 $ 2.98 7.71 — Vested and expected as of March 31, 2022 1,440,785 $ 3.00 7.90 $ — The fair value of stock options granted are recognized as compensation expense in the consolidated statements of operations over the related vesting periods. As of March 31, 2022 (unaudited), there was approximately $1.2 million of unrecognized stock-based compensation cost related to stock options granted under the Plan, respectively, which is expected to be recognized over an average period of 1.95 years. The following table illustrates stock-based compensation expense for employee and non-employee RSUs and options for the three months ended March 31, 2022 and 2021 (unaudited) (in thousands). Three Months Ended 2022 2021 (unaudited) Cost of revenues $ 304 $ 41 Research and development 883 226 Sales and marketing 344 17 Other operating expenses 3,727 2,924 Total stock-based compensation $ 5,258 $ 3,208 |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income TaxesThe consolidated effective tax rate for both the three months ended March 31, 2022 and 2021 (unaudited), was 0%. The main driver of the difference between the federal statutory tax rate of 21% and the effective tax rate for both periods was primarily related to a full valuation allowance against the deferred tax assets. |
Segment and Geographic Informat
Segment and Geographic Information | 3 Months Ended |
Mar. 31, 2022 | |
Segment Reporting [Abstract] | |
Segment and Geographic Information | Segment and Geographic Information The Company operates in the following two reportable segments, which are the same as its operating segments: – Insurance Services. Providing insurance policies for automobile owners – Enterprise Business Solutions. Providing access to its developed technology under SaaS arrangements along with professional services to third party customers. Operating segments are based upon the nature of the Company’s business and how its business is managed. The Company’s Chief Operating Decision Maker (“CODM”) is its CEO. The CODM uses the Company’s operating segment financial information to evaluate segment performance and to allocate resources. The CODM does not evaluate the performance of the Company’s assets on a segment basis for internal management reporting and, therefore, such information is not presented. Contribution is used, in part, to evaluate the performance of, and allocate resources to, each of the segments. Segment contribution is segment revenue less the related costs of revenue and sales and marketing expenses. It excludes certain operating expenses that are not allocated to segments because they are separately managed at the consolidated corporate level. These unallocated costs include stock-based compensation expense, research and development expenses, and general and administrative expenses such as legal and accounting. The assets and liabilities of the Enterprise Business Solutions segment have been classified as held for sale in the Company's consolidated balance sheets as of March 31, 2022. As the Enterprise Business Solutions operations do not qualify for presentation as a discontinued operation, operating results from the segment will continue to be reported in continuing operations on the consolidated statements of operations for the period ended March 31, 2022. Refer to Note 16, Business Disposition, for further information The following table summarizes the operating results of the Company’s reportable segments (in thousands): Three Months Ended 2022 2021 (unaudited) Revenue: Insurance services $ 19,503 $ 16,228 Enterprise business solutions 1,196 1,048 Total revenue $ 20,699 $ 17,276 Contribution: Insurance services $ (4,419) $ (1,863) Enterprise business solutions (1,113) (732) Total contribution $ (5,532) $ (2,595) The following table provides a reconciliation of the Company’s total reportable segments’ contribution to its total loss from operations (in thousands): Three Months Ended 2022 2021 (unaudited) Total segment contribution $ (5,532) $ (2,595) Ceded premium, losses and LAE 1,293 (2,905) Other income 522 1,147 Policy services expenses and other 1,606 371 Sales, marketing, and other acquisition costs 6,340 47,167 Research and development 2,351 2,006 Amortization of capitalized software 3,368 2,651 Other operating expenses 13,438 8,582 Loss from operations $ (34,450) $ (61,614) Total other expense (131) 42,013 Loss before taxes $ (34,319) $ (103,627) Geographical Breakdown of Direct Earned Premiums Direct earned premium by state is as follows (in thousands): Three Months Ended 2022 2021 (unaudited) California $ 15,760 $ 15,146 Washington 3,585 2,985 New Jersey 2,682 2,459 Oregon 1,816 1,796 Illinois 1,138 1,041 Arizona 1,759 1,268 Pennsylvania 635 657 Virginia 756 470 Total premiums earned $ 28,131 $ 25,822 |
Net Loss per Share
Net Loss per Share | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss per Share | Net Loss per Share Net loss per share calculations and potentially dilutive security amounts for all periods prior to the Merger have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Merger to effect the reverse recapitalization. Historically, reported weighted average shares outstanding have been multiplied by 1.01547844, which is the share exchange ratio established by the Merger Agreement. The following table sets forth the computation of basic and diluted net loss per share attributable to the Company's common stockholders: Three months ended March 31, 2022 2021 Numerator: (unaudited) Net loss attributable to common stockholders ($ in thousands) $ (34,319) $ (103,627) Denominator: Weighted average common shares outstanding - basic and diluted 128,715,031 75,791,557 Net loss per share attributable to common stockholders - basic and diluted $ (0.27) $ (1.37) As the Company has reported net loss for each of the periods presented, all potentially dilutive securities are antidilutive. The following potential outstanding shares of Common Stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of March 31, 2022 2021 (unaudited) Convertible preferred stock — — Outstanding stock options - Stock Plan 1,657,173 4,595,624 Warrants for preferred stock — — Warrants for common stock 7,846,667 7,846,667 Restricted stock units 9,161,160 8,333 Total anti-dilutive securities 18,665,000 12,450,624 |
Related-Party Transactions
Related-Party Transactions | 3 Months Ended |
Mar. 31, 2022 | |
Related Party Transactions [Abstract] | |
Related-Party Transactions | Related-Party Transactions In August 2014, the Company loaned the CEO $0.4 million with interest at 3.09% and adjusted to 1.5% in April 2020, which was used to early exercise stock options issued to the CEO and was due at the earlier of one year after termination of employment, upon an Initial Public Offering or change in control, or ten years from the date issued. The loan was full recourse, and also collateralized by the underlying shares of common stock. For accounting under GAAP, the note receivable is presented as contra-equity in the accompanying consolidated balance sheets. This loan was paid in full in February 2021 and is no longer outstanding. In March 2018, the Company entered into an agreement with a third party under which the Company developed proprietary software solutions and provides access to and use of such software solutions and related services. In July 2018, the third party became an investor of the Company as part of the Series E convertible preferred stock Financing. During both the three months ended March 31, 2022 and 2021 (unaudited), the Company recognized $1.0 million of revenue from the investor. The Company had $1.5 million and $0 million in accounts receivable balances from the investor as of March 31, 2022 (unaudited) and December 31, 2021, respectively. The Company continues to enter into contracts with the investor related to the Company’s Enterprise Business Solutions (see Note 13, Segment and Geographic Information). An executive of Hudson, who the Company entered into a Note Purchase and Security Agreement with in 2021 (see Note 11, Notes Payable, net in the Company's 2021 Annual Report on Form 10-K), is on the Company’s Board of Directors. This loan was repaid in March 2021 and is no longer outstanding. |
Business Disposition
Business Disposition | 3 Months Ended |
Mar. 31, 2022 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Business Disposition | Business Disposition Sale of Metromile Enterprise As of March 31, 2022, the Company committed to a plan to sell its Enterprise Business Solutions segment. The assets and liabilities of Enterprise Business Solutions have been classified as held for sale in the Company's consolidated balance sheets beginning with the period ended March 31, 2022. Revenues and earnings are not material to the Company's Consolidated Results of Operations for the three months ended March 31, 2022 and 2021 (unaudited). Under GAAP accounting guidance, only disposals of components of an entity that represent a strategic shift and that have a major effect on a reporting entity’s operations and financial results are reported as discontinued operations. Because Metromile’s primary business continues to be property and casualty insurance, as well as the immaterial expected impact on the Company’s ongoing results of operations, the sale of Enterprise Business Solutions was not reported as a discontinued operation. The business does not meet the criteria to be classified as a discontinued operation; therefore, the results are reflected within continuing operations on the consolidated statement of operations. The pending sale did not result in an estimated loss on the sale, and as such, no accrual for the estimated before tax loss is included as a reduction of the carrying value of assets held for sale in the Company's Condensed consolidated balance sheets as of March 31, 2022 (unaudited). The carrying value of assets and liabilities to be transferred in connection with the sale is as follows: March 31, (unaudited) Assets Cash and cash equivalents 2,393 Prepaid expenses and other assets 1,705 Website and software development costs, net 5,155 Total assets $ 9,253 Liabilities Deferred revenue 5,906 Accounts payable and accrued expenses 250 Total liabilities $ 6,156 |
Overview and Basis of Present_2
Overview and Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying interim unaudited consolidated financial statements have been prepared in accordance GAAP and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). References to the Accounting Standard Codification (“ASC”) and Accounting Standard Updates (“ASU”) included hereinafter refer to the Accounting Standards Codification and Updates established by the Financial Accounting Standards Board (“FASB”) as the source of authoritative GAAP. The consolidated financial statements include the accounts of Metromile, Inc. and its subsidiaries, all of which are wholly owned. All intercompany accounts and transactions have been eliminated in consolidation. These unaudited consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 ("the Company’s 2021 Annual Report"). |
Reclassifications | Reclassifications Reclassifications have been made to the prior year balances to conform to the current year presentation. In particular, accounts receivable, and digital assets, net have been combined with prepaid expenses and other assets into a single line on the consolidated balance sheets and consolidated statements of cash flows. The reclassifications had no effect on stockholders’ deficit or net loss after taxes as previously reported. |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to contingent assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the reporting period. The Company’s principal estimates include: unpaid losses and LAE reserves; the fair value of investments; the fair value of stock-based awards; the fair value of the warrant liability; premium refunds to policyholders; reinsurance recoverable on unpaid loss; and the valuation allowance for income taxes. Because of uncertainties associated with estimating the amounts, timing and likelihood of possible outcomes, actual results could differ materially from these estimates. |
Discontinued Operations and Held for Sale | Discontinued Operations and Held for Sale A business is classified as held for sale when management having the authority to approve the action commits to a plan to sell the business, the sale is probable to occur during the next 12 months at a price that is reasonable in relation to its current fair value and certain other criteria are met. A business classified as held for sale is recorded at the lower of its carrying amount or estimated fair value less cost to sell. When the carrying amount of the business exceeds its estimated fair value less cost to sell, a loss is recognized and updated each reporting period as appropriate. The results of operations of business classified as held for sale are reported as discontinued operations if the disposal represents a strategic shift that will have a major effect on the entity’s operations and financial results. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements Reference Rate Reform In March 2020, FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued. The standard is effective upon issuance through December 31, 2022 and may be applied at the beginning of the interim period that includes March 12, 2020 or any date thereafter. The Company is currently evaluating this new standard and the impact it will have on its consolidated financial statements. This standard may be elected and applied prospectively over time from March, 2020 through December 31, 2022 as reference rate reform activities occur. The Company is evaluating the method of adoption and impact of the standard on its consolidated financial statements and related disclosures. Government Assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The amendments should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company is currently evaluating the impact of these amendments on its consolidated financial statements. |
Fair Value Measurement | Topic 820, Fair Value Measurements , defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Topic 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a description of the valuation methodologies used for instruments measured at fair value on a recurring basis and recognized in the accompanying Consolidated Balance Sheet, as well as the general classification of such instruments pursuant to the valuation hierarchy. Cash and Cash Equivalents The Company’s cash and cash equivalents are demand and money market accounts and other highly liquid investments with an original maturity of three months or less. Demand and money market accounts are at stated values. Fair values for other cash equivalents are classified as Level 1 and are based upon appropriate valuation methodology. Marketable Securities — Available-for-sale The Company classifies highly liquid money market funds, U.S. Treasury bonds and certificates of deposit within Level 1 of the fair value hierarchy because they are valued based on quoted market prices in active markets and upon models that take into consideration such market-based factors as recent sales, risk-free yield curves, and prices of similarly rated bonds. Commercial paper, corporate bonds, corporate debt securities, repurchase agreements, and asset backed securities are classified within Level 2 because they are valued using inputs other than quoted prices that are directly or indirectly observable in the market, including readily available pricing sources for the identical underlying security which may not be actively traded. The Company did not hold any securities classified within Level 3 as of March 31, 2022 (unaudited) and December 31, 2021. Public and Private Warrants At the Closing, Metromile Operating Company acquired the net liabilities from INSU, including warrants exercisable for common stock. The Company estimated the fair value of warrants exercisable for common stock measured at fair value on a recurring basis at the respective dates using the public trading price, for the Public warrants, and the Black-Scholes option valuation model, for the Private placement warrants (together with the public warrants, the “Warrants”), respectively. The Black-Scholes option valuation model inputs are based on the estimated fair value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, the risk-free interest rates, the expected dividends, and the expected volatility of the price of the Company’s underlying stock. These estimates, especially the expected volatility, are highly judgmental and could differ materially in the future. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. The Company considers its Public warrants to be Level 1 liabilities as it uses publicly and readily available information to measure the fair value of the warrants. For the Company's Private placement warrants, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date and as such are classified as Level 2 liabilities. |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of assets measured on a recurring basis at fair value | Assets measured on a recurring basis at fair value, primarily related to marketable securities, included in the consolidated balance sheets as of March 31, 2022 (unaudited) and December 31, 2021 are set forth below (in thousands): Fair Value Measurement at March 31, 2022 (unaudited) Level 1 Level 2 Level 3 Total Cash equivalents Money market accounts $ 79,039 $ — $ — $ 79,039 Total cash equivalents $ 79,039 $ — $ — $ 79,039 Restricted cash equivalents Money market accounts $ 14,662 $ — $ — $ 14,662 Certificates of deposits 3,031 — — 3,031 Total restricted cash equivalents $ 17,693 $ — $ — $ 17,693 Marketable securities - restricted Corporate debt securities $ — $ 2,738 $ — $ 2,738 U.S. treasury and agency securities 37,693 1,956 — 39,649 Commercial paper — 18,550 — 18,550 Asset backed securities — 6,212 — 6,212 Total marketable securities - restricted $ 37,693 $ 29,456 $ — $ 67,149 Fair Value Measurement at December 31, 2021 Level 1 Level 2 Level 3 Total Cash equivalents Money market accounts $ 113,402 $ — $ — $ 113,402 Total cash equivalents $ 113,402 $ — $ — $ 113,402 Restricted cash equivalents Money market accounts $ 19,569 $ — $ — $ 19,569 Certificates of deposits 3,331 — — 3,331 Total restricted cash equivalents $ 22,900 $ — $ — $ 22,900 Marketable securities - restricted Corporate debt securities $ — $ 2,545 $ — $ 2,545 U.S. treasury securities 33,295 1,986 — 35,281 Commercial paper — 16,081 — 16,081 Asset backed securities — 8,718 — 8,718 Total marketable securities - restricted $ 33,295 $ 29,330 $ — $ 62,625 |
Fair value of warrants | The table below sets forth a summary of changes in the fair value of the Company’s Level 1, Level 2, and Level 3 liabilities for the year ended December 31, 2021 and the three months ended March 31, 2022 (unaudited) (in thousands): Balance at December 31, 2020 $ 83,652 Increase in fair value of warrants 47,062 Exercise of preferred stock warrants prior to Business Combination (130,714) Public and Private placement Warrants acquired in Business Combination 45,623 Decrease in fair value of Public and Private placement Warrants (44,467) Balance at December 31, 2021 $ 1,156 Decrease in fair value of warrants (131) Balance at March 31, 2022 $ 1,025 |
Schedule of Black-Scholes option valuation model | The fair value of the Private placement warrants was determined using the Black-Scholes option valuation model using the following assumptions for values as of March 31, 2022: Estimated Fair Value of Warrants as of March 31, Exercise Dividend Volatility Risk-Free Expected (in thousands) (in whole dollars) (in years) Private placement warrants $ 28.8 $ 11.50 0 % 75 % 2.44 % 3.86 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of available-for-sale securities | The amortized cost and fair value of investments in fixed maturities classified as available-for-sale as of March 31, 2022 (unaudited) and December 31, 2021 are presented below (in thousands): As of March 31, 2022 (Unaudited) Amortized ACL Unrealized Unrealized Estimated Marketable securities - restricted Corporate debt securities $ 2,741 $ — $ — $ (3) $ 2,738 U.S. treasury and agency securities 40,088 — — (439) 39,649 Commercial paper 18,550 — — — 18,550 Asset backed securities 6,234 — — (22) 6,212 Total marketable securities - restricted $ 67,613 $ — $ — $ (464) $ 67,149 As of December 31, 2021 Amortized ACL Unrealized Unrealized Estimated Marketable securities - restricted Corporate debt securities $ 2,547 $ — $ — $ (2) $ 2,545 U.S. treasury securities 35,385 — — (104) 35,281 Commercial paper 16,081 — — — 16,081 Asset backed securities 8,728 — — (10) 8,718 Total marketable securities - restricted $ 62,741 $ — $ — $ (116) $ 62,625 |
Schedule of amortized cost and estimated fair value of marketable securities | The amortized cost and estimated fair value of marketable securities as of March 31, 2022 (unaudited) and December 31, 2021 and are shown below by contractual maturity (in thousands): As of March 31, Amortized Estimated Due within one year $ 52,471 $ 52,298 Due between one to five years 15,142 14,851 $ 67,613 $ 67,149 As of December 31, Amortized Estimated Due within one year $ 41,603 $ 41,596 Due between one to five years 21,138 21,029 $ 62,741 $ 62,625 |
Schedule of unrealized loss on investments | The following table summarizes, for all fixed maturities classified as available-for-sale in an unrealized loss position at March 31, 2022, the aggregate fair value and gross unrealized loss by length of time those securities have been continuously in an unrealized loss position. The fair value amounts reported in the tables are estimates that are prepared using the process described in Note 2, Fair Value. The Company also relies upon estimates of several factors in its review and evaluation of individual investments, using the process described in Note 1, Basis of Presentation and Significant Accounting Policies in the Company’s 2021 Annual Report in determining whether a credit loss impairment exists. As of March 31, 2022 (unaudited) Less Than 12 Months 12 Months or Longer Total Fair Value Unrealized Fair Value Unrealized Fair Value Unrealized Marketable securities - restricted Corporate debt securities $ 732 $ (3) $ — $ — $ 732 $ (3) U.S. treasury and agency securities 39,649 (439) — — 39,649 (439) Commercial paper 1,006 — — — 1,006 — Asset backed securities 6,212 (22) — — 6,212 (22) Total in an unrealized loss position $ 47,599 $ (464) $ — $ — $ 47,599 $ (464) As of December 31, 2021 Less Than 12 Months 12 Months or Longer Total Fair Value Unrealized Fair Value Unrealized Fair Value Unrealized Marketable securities - restricted Corporate debt securities $ 737 $ (2) $ — $ — $ 737 $ (2) U.S. treasury and agency securities 31,809 (104) — — 31,809 (104) Commercial paper 1,808 — — — 1,808 — Asset backed securities 8,716 (10) — — 8,716 (10) Total in an unrealized loss position $ 43,070 $ (116) $ — $ — $ 43,070 $ (116) |
Business Combination (Tables)
Business Combination (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Reverse Recapitalization [Abstract] | |
Schedule of business combination proceeds | The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of stockholders’ equity for the three months ended March 31, 2021 (dollars in thousands). Recapitalization Cash – INSU’s trust and cash (net of redemptions) $ 229,925 Cash – PIPE 170,000 Less transaction costs and advisory fees paid 31,456 Less cash payments to Metromile Operating Company stockholders 32,000 Net Business Combination and PIPE financing 336,469 Less non-cash net liabilities assumed from INSU 45,516 Net contributions from Business Combination and PIPE Financing $ 290,953 |
Schedule of equity changes due to business combination | Number of Shares INSU Class A Common stock, outstanding prior to Business Combination 23,540,000 INSU Class B Common stock, outstanding prior to Business Combination 6,669,667 Less redemption of INSU shares 8,372 Common stock of INSU 30,201,295 Shares issued in PIPE 17,000,000 Business Combination and PIPE financing shares 47,201,295 Metromile Operating Company shares (1) 79,525,839 Total shares of common stock immediately after Business Combination 126,727,134 (1) The number of Metromile Operating Company shares was determined from the 78,313,665 shares of Metromile Operating Company common and preferred stock outstanding immediately prior to the closing of the Business Combination, which are presented net of the common and preferred stock redeemed, converted at the Exchange Ratio of 1.01547844. All fractional shares were rounded down. |
Deferred Policy Acquisition C_2
Deferred Policy Acquisition Costs, Net (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Deferred Policy Acquisition Costs Disclosures [Abstract] | |
Schedule of deferred policy acquisition costs | Deferred policy acquisition costs, net ("DPAC") consists of the following (in thousands): March 31, December 31, (unaudited) Deferred policy acquisition costs $ 11,655 $ 11,533 Deferred ceding commission (181) (114) Accumulated amortization (10,270) (9,986) Deferred policy acquisition costs, net $ 1,204 $ 1,433 |
Loss and Loss Adjustment Expe_2
Loss and Loss Adjustment Expense Reserves (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Insurance [Abstract] | |
Schedule of beginning and ending reserve balances for losses and LAE, net of reinsurance recoverable | The following table provides a reconciliation of the beginning and ending reserve balances for losses and LAE, net of reinsurance recoverable, for the three months ended March 31, 2021 and 2022 (unaudited) (in thousands): Three Months Ended 2022 2021 (unaudited) Balance at January 1 $ 73,438 $ 57,093 Less reinsurance recoverable — (33,941) Net balance at January 1 73,438 23,152 Incurred related to: Current year 21,874 9,566 Prior years 96 2,664 Total incurred 21,970 12,230 Paid related to: Current year 8,035 695 Prior years 14,865 (18,200) Total paid 22,900 (17,505) Net balance at end of period 72,508 52,887 Plus reinsurance recoverable 4,408 8,694 Balance at end of period $ 76,916 $ 61,581 |
Reinsurance (Tables)
Reinsurance (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Reinsurance Disclosures [Abstract] | |
Schedule of effects of reinsurance | The effect of the Company’s reinsurance agreements on premiums, loss and LAE related to the insurance company for the three months ended March 31, 2022 (unaudited) and the year ended December 31, 2021 is as follows (in thousands): March 31, 2022 (unaudited) Premium Premium Unearned Losses and LAE Loss and LAE Direct $ 29,328 $ 28,131 $ 16,924 $ 29,072 $ 76,916 Ceded (8,798) (8,440) (359) (7,102) (4,408) Net $ 20,530 $ 19,691 $ 16,565 $ 21,970 $ 72,508 December 31, 2021 Premium Premium Unearned Losses and LAE Loss and LAE Direct $ 110,719 $ 111,063 $ 15,726 $ 102,991 $ 73,438 Ceded (19,411) (33,080) — (14,701) — Net $ 91,308 $ 77,983 $ 15,726 $ 88,290 $ 73,438 |
Stock Option Plans (Tables)
Stock Option Plans (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of restricted stock units | A summary of the Company’s RSUs as of March 31, 2022 (unaudited) is presented in the table below: Number of RSUs Weighted-Average Fair Balance at December 31, 2021 7,241,980 $ 8.19 Granted 819,227 1.28 Vested (496,366) 10.15 Forfeited (620,551) 6.03 Balance at March 31, 2022 6,944,290 $ 7.43 |
Schedule of estimate the value of options granted | The following assumptions were used to estimate the value of options granted during the year ended December 31, 2021: Year ended December 31, Forfeiture rate 26.2 % Volatility 62.00 % Expected term (years) 5.33 Risk-free interest rate 0.53 % Expected dividends — |
Schedule of activity of stock option plan | The following table summarizes the activity of the Company’s stock option plan as of March 31, 2022 (unaudited): Stock Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 2,374,504 $ 3.00 8.25 $ 375 Options granted — $ — Options exercised — $ — Options cancelled or expired and returned to plan (717,331) $ 3.00 Outstanding as of March 31, 2022 1,657,173 $ 3.01 7.94 $ — Vested and exercisable to vest as of March 31, 2022 723,575 $ 2.98 7.71 — Vested and expected as of March 31, 2022 1,440,785 $ 3.00 7.90 $ — |
Schedule of stock-based compensation expense for employee and nonemployee options | The following table illustrates stock-based compensation expense for employee and non-employee RSUs and options for the three months ended March 31, 2022 and 2021 (unaudited) (in thousands). Three Months Ended 2022 2021 (unaudited) Cost of revenues $ 304 $ 41 Research and development 883 226 Sales and marketing 344 17 Other operating expenses 3,727 2,924 Total stock-based compensation $ 5,258 $ 3,208 |
Segment and Geographic Inform_2
Segment and Geographic Information (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Segment Reporting [Abstract] | |
Schedule of operating results of the Company’s reportable segments | The following table summarizes the operating results of the Company’s reportable segments (in thousands): Three Months Ended 2022 2021 (unaudited) Revenue: Insurance services $ 19,503 $ 16,228 Enterprise business solutions 1,196 1,048 Total revenue $ 20,699 $ 17,276 Contribution: Insurance services $ (4,419) $ (1,863) Enterprise business solutions (1,113) (732) Total contribution $ (5,532) $ (2,595) |
Schedule of contribution to its total loss from operations | The following table provides a reconciliation of the Company’s total reportable segments’ contribution to its total loss from operations (in thousands): Three Months Ended 2022 2021 (unaudited) Total segment contribution $ (5,532) $ (2,595) Ceded premium, losses and LAE 1,293 (2,905) Other income 522 1,147 Policy services expenses and other 1,606 371 Sales, marketing, and other acquisition costs 6,340 47,167 Research and development 2,351 2,006 Amortization of capitalized software 3,368 2,651 Other operating expenses 13,438 8,582 Loss from operations $ (34,450) $ (61,614) Total other expense (131) 42,013 Loss before taxes $ (34,319) $ (103,627) |
Schedule of geographical breakdown of direct earned premiums | Direct earned premium by state is as follows (in thousands): Three Months Ended 2022 2021 (unaudited) California $ 15,760 $ 15,146 Washington 3,585 2,985 New Jersey 2,682 2,459 Oregon 1,816 1,796 Illinois 1,138 1,041 Arizona 1,759 1,268 Pennsylvania 635 657 Virginia 756 470 Total premiums earned $ 28,131 $ 25,822 |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of basic and diluted net loss per share | The following table sets forth the computation of basic and diluted net loss per share attributable to the Company's common stockholders: Three months ended March 31, 2022 2021 Numerator: (unaudited) Net loss attributable to common stockholders ($ in thousands) $ (34,319) $ (103,627) Denominator: Weighted average common shares outstanding - basic and diluted 128,715,031 75,791,557 Net loss per share attributable to common stockholders - basic and diluted $ (0.27) $ (1.37) |
Schedule of antidilutive securities excluded from computation of earnings per share | The following potential outstanding shares of Common Stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of March 31, 2022 2021 (unaudited) Convertible preferred stock — — Outstanding stock options - Stock Plan 1,657,173 4,595,624 Warrants for preferred stock — — Warrants for common stock 7,846,667 7,846,667 Restricted stock units 9,161,160 8,333 Total anti-dilutive securities 18,665,000 12,450,624 |
Business Disposition (Tables)
Business Disposition (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Summary of carrying value of assets and liabilities to be transferred in connection with the sale | The carrying value of assets and liabilities to be transferred in connection with the sale is as follows: March 31, (unaudited) Assets Cash and cash equivalents 2,393 Prepaid expenses and other assets 1,705 Website and software development costs, net 5,155 Total assets $ 9,253 Liabilities Deferred revenue 5,906 Accounts payable and accrued expenses 250 Total liabilities $ 6,156 |
Overview and Basis of Present_3
Overview and Basis of Presentation (Details) | Nov. 08, 2021USD ($)$ / shares | Feb. 09, 2021USD ($)$ / sharesshares | Sep. 08, 2020USD ($)$ / sharesshares | Mar. 31, 2021 | Mar. 31, 2022USD ($)state$ / shares | Dec. 31, 2021USD ($)$ / shares |
Business Description And Accounting Policies [Line Items] | ||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.0001 | |||||
Purchase price (in dollars per share) | $ / shares | $ 10 | |||||
Other offering costs | $ | $ 14,200,000 | |||||
Underwriting fees | $ | 4,000,000 | |||||
Deferred underwriting fees | $ | $ 9,800,000 | |||||
Business combination converted exchange ratio | 1.01547844 | |||||
Common stock par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||||
Sale of stock (in shares) | shares | 17,000,000 | |||||
Aggregate purchase price | $ | $ 170,000,000 | |||||
Number of states in which entity operates | state | 8 | |||||
Loss and LAE reserves | $ | $ 76,900,000 | $ 73,400,000 | ||||
Lemonade, Inc. | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Common stock par value (in dollars per share) | $ / shares | $ 0.00001 | |||||
Lemonade, Inc. | Metromile, Inc. | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Fully diluted equity value | $ | $ 500,000,000 | |||||
Equity value, net of unrestricted cash and cash equivalents | $ | $ 340,000,000 | |||||
Business combination converted exchange ratio | 0.05263 | |||||
Common stock par value (in dollars per share) | $ / shares | $ 0.00001 | |||||
IPO | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Sale of stock (in shares) | shares | 23,000,000 | |||||
Other offering costs | $ | $ 400,000 | |||||
Over-Allotment Option | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Sale of stock (in shares) | shares | 3,000,000 | |||||
Purchase price (in dollars per share) | $ / shares | $ 10 | |||||
Gross proceeds | $ | $ 230,000,000 | |||||
Private Placement | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Purchase price (in dollars per share) | $ / shares | $ 10 | |||||
Sale of stock (in shares) | shares | 540,000 | |||||
Gross proceeds from private placement | $ | $ 5,400,000 | |||||
Sale per unit (in dollars per share) | $ / shares | $ 10 | |||||
Common Class A | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Common stock, par value (in dollars per share) | $ / shares | 0.0001 | |||||
Class B Common Stock | ||||||
Business Description And Accounting Policies [Line Items] | ||||||
Share price (in dollars per share) | $ / shares | $ 0.0001 | |||||
Share conversion ratio | 1 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Schedule of assets measured on a recurring basis at fair value (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Cash equivalents | ||
Total cash equivalents | $ 79,039 | $ 113,402 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 17,693 | 22,900 |
Marketable securities - restricted | ||
Total marketable securities - restricted | 67,149 | 62,625 |
Money market accounts | ||
Cash equivalents | ||
Total cash equivalents | 79,039 | 113,402 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 14,662 | 19,569 |
Certificates of deposits | ||
Restricted cash equivalents | ||
Total restricted cash equivalents | 3,031 | 3,331 |
Corporate debt securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 2,738 | 2,545 |
U.S. treasury and agency securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 39,649 | 35,281 |
Commercial paper | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 18,550 | 16,081 |
Asset backed securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 6,212 | 8,718 |
Level 1 | ||
Cash equivalents | ||
Total cash equivalents | 79,039 | 113,402 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 17,693 | 22,900 |
Marketable securities - restricted | ||
Total marketable securities - restricted | 37,693 | 33,295 |
Level 1 | Money market accounts | ||
Cash equivalents | ||
Total cash equivalents | 79,039 | 113,402 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 14,662 | 19,569 |
Level 1 | Certificates of deposits | ||
Restricted cash equivalents | ||
Total restricted cash equivalents | 3,031 | 3,331 |
Level 1 | Corporate debt securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 1 | U.S. treasury and agency securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 37,693 | 33,295 |
Level 1 | Commercial paper | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 1 | Asset backed securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 2 | ||
Cash equivalents | ||
Total cash equivalents | 0 | 0 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 0 | 0 |
Marketable securities - restricted | ||
Total marketable securities - restricted | 29,456 | 29,330 |
Level 2 | Money market accounts | ||
Cash equivalents | ||
Total cash equivalents | 0 | 0 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 0 | 0 |
Level 2 | Certificates of deposits | ||
Restricted cash equivalents | ||
Total restricted cash equivalents | 0 | 0 |
Level 2 | Corporate debt securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 2,738 | 2,545 |
Level 2 | U.S. treasury and agency securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 1,956 | 1,986 |
Level 2 | Commercial paper | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 18,550 | 16,081 |
Level 2 | Asset backed securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 6,212 | 8,718 |
Level 3 | ||
Cash equivalents | ||
Total cash equivalents | 0 | 0 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 0 | 0 |
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 3 | Money market accounts | ||
Cash equivalents | ||
Total cash equivalents | 0 | 0 |
Restricted cash equivalents | ||
Total restricted cash equivalents | 0 | 0 |
Level 3 | Certificates of deposits | ||
Restricted cash equivalents | ||
Total restricted cash equivalents | 0 | 0 |
Level 3 | Corporate debt securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 3 | U.S. treasury and agency securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 3 | Commercial paper | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | 0 | 0 |
Level 3 | Asset backed securities | ||
Marketable securities - restricted | ||
Total marketable securities - restricted | $ 0 | $ 0 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Schedule of warrant liability (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Balance, beginning of period | $ 1,156 | $ 83,652 |
Increase in fair value of warrant | 47,062 | |
Exercise of preferred stock warrants prior to Business Combination | (130,714) | |
Public and Private placement Warrants acquired in Business Combination | 45,623 | |
Decrease in fair value of Public and Private placement Warrants | (131) | (44,467) |
Balance, end of period | $ 1,025 | $ 1,156 |
Fair Value of Financial Instr_5
Fair Value of Financial Instruments - Schedule of Black-Scholes option valuation model (Details) | Mar. 31, 2022USD ($) |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrant liability | $ 28,800 |
Exercise Price | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Private placement warrants | 11.50 |
Dividend Yield | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Private placement warrants | 0 |
Volatility | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Private placement warrants | 0.75 |
Risk-Free Interest Rate | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Private placement warrants | 0.0244 |
Expected Term | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Private placement warrants | 3.86 |
Fair Value of Financial Instr_6
Fair Value of Financial Instruments - Narrative (Details) | Dec. 31, 2020shares |
Warrants for preferred stock | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Number of warrants outstanding (in shares) | 0 |
Marketable Securities (Details)
Marketable Securities (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Investments, Debt and Equity Securities [Abstract] | ||
Marketable securities bonds with carrying values | $ 5.2 | $ 5.2 |
Marketable Securities - Schedul
Marketable Securities - Schedule of available-for-sale securities (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | $ 67,613 | $ 62,741 |
ACL | 0 | 0 |
Unrealized Gain | 0 | 0 |
Unrealized Loss | (464) | (116) |
Estimated Fair Value | 67,149 | 62,625 |
Corporate debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 2,741 | 2,547 |
ACL | 0 | 0 |
Unrealized Gain | 0 | 0 |
Unrealized Loss | (3) | (2) |
Estimated Fair Value | 2,738 | 2,545 |
U.S. treasury securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 40,088 | 35,385 |
ACL | 0 | 0 |
Unrealized Gain | 0 | 0 |
Unrealized Loss | (439) | (104) |
Estimated Fair Value | 39,649 | 35,281 |
Commercial paper | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 18,550 | 16,081 |
ACL | 0 | 0 |
Unrealized Gain | 0 | 0 |
Unrealized Loss | 0 | 0 |
Estimated Fair Value | 18,550 | 16,081 |
Asset backed securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 6,234 | 8,728 |
ACL | 0 | 0 |
Unrealized Gain | 0 | 0 |
Unrealized Loss | (22) | (10) |
Estimated Fair Value | $ 6,212 | $ 8,718 |
Marketable Securities - Sched_2
Marketable Securities - Schedule of amortized cost and estimated fair value of marketable securities (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Debt Securities, Available-for-sale [Line Items] | ||
Due within one year | $ 52,471 | $ 41,603 |
Due between one to five years | 15,142 | 21,138 |
Total | 67,613 | 62,741 |
Estimated Fair Value | ||
Debt Securities, Available-for-sale [Line Items] | ||
Due within one year | 52,298 | 41,596 |
Due between one to five years | 14,851 | 21,029 |
Total | $ 67,149 | $ 62,625 |
Marketable Securities - Continu
Marketable Securities - Continuous loss position (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Fair Value | ||
Less Than 12 Months | $ 47,599 | $ 43,070 |
12 Months or Longer | 0 | 0 |
Total | 47,599 | 43,070 |
Unrealized Losses | ||
Less Than 12 Months | (464) | (116) |
12 Months or Longer | 0 | 0 |
Total | (464) | (116) |
Corporate debt securities | ||
Fair Value | ||
Less Than 12 Months | 732 | 737 |
12 Months or Longer | 0 | 0 |
Total | 732 | 737 |
Unrealized Losses | ||
Less Than 12 Months | (3) | (2) |
12 Months or Longer | 0 | 0 |
Total | (3) | (2) |
U.S. treasury and agency securities | ||
Fair Value | ||
Less Than 12 Months | 39,649 | 31,809 |
12 Months or Longer | 0 | 0 |
Total | 39,649 | 31,809 |
Unrealized Losses | ||
Less Than 12 Months | (439) | (104) |
12 Months or Longer | 0 | 0 |
Total | (439) | (104) |
Commercial paper | ||
Fair Value | ||
Less Than 12 Months | 1,006 | 1,808 |
12 Months or Longer | 0 | 0 |
Total | 1,006 | 1,808 |
Unrealized Losses | ||
Less Than 12 Months | 0 | 0 |
12 Months or Longer | 0 | 0 |
Total | 0 | 0 |
Asset backed securities | ||
Fair Value | ||
Less Than 12 Months | 6,212 | 8,716 |
12 Months or Longer | 0 | 0 |
Total | 6,212 | 8,716 |
Unrealized Losses | ||
Less Than 12 Months | (22) | (10) |
12 Months or Longer | 0 | 0 |
Total | $ (22) | $ (10) |
Business Combination - Schedule
Business Combination - Schedule of business combination proceeds (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Reverse Recapitalization [Abstract] | |
Cash – INSU’s trust and cash (net of redemptions) | $ 229,925 |
Cash – PIPE | 170,000 |
Less transaction costs and advisory fees paid | 31,456 |
Less cash payments to Metromile Operating Company stockholders | 32,000 |
Net Business Combination and PIPE financing | 336,469 |
Less non-cash net liabilities assumed from INSU | 45,516 |
Net contributions from Business Combination and PIPE Financing | $ 290,953 |
Business Combination - Schedu_2
Business Combination - Schedule of equity changes due to business combination (Details) | 3 Months Ended |
Mar. 31, 2021shares | |
Reverse Recapitalization [Abstract] | |
INSU Class A Common stock, outstanding prior to Business Combination (in shares) | 23,540,000 |
INSU Class B Common stock, outstanding prior to Business Combination (in shares) | 6,669,667 |
Less redemption of INSU shares (in shares) | 8,372 |
Common stock of INSU (in shares) | 30,201,295 |
Shares issued in PIPE (in shares) | 17,000,000 |
Business Combination and PIPE financing shares (in shares) | 47,201,295 |
Metromile Operating Company shares (in shares) | 79,525,839 |
Total shares of common stock immediately after Business Combination (in shares) | 126,727,134 |
Common and preferred stock outstanding (in shares) | 78,313,665 |
Business combination converted exchange ratio | 1.01547844 |
Business Combination - Narrativ
Business Combination - Narrative (Details) $ / shares in Units, $ in Millions | Nov. 08, 2021USD ($)tradingDay$ / shares | Mar. 31, 2022USD ($)tradingDay$ / shares | Mar. 31, 2021 | Dec. 31, 2021$ / shares |
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Business combination converted exchange ratio | 1.01547844 | |||
Common stock par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||
Trading days | tradingDay | 20 | |||
Lemonade, Inc. | ||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Common stock par value (in dollars per share) | $ / shares | $ 0.00001 | |||
Metromile, Inc. | Lemonade, Inc. | ||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Fully diluted equity value | $ 500 | |||
Equity value, net of unrestricted cash and cash equivalents | $ 340 | |||
Business combination converted exchange ratio | 0.05263 | |||
Common stock par value (in dollars per share) | $ / shares | $ 0.00001 | |||
Trading days | tradingDay | 20 | |||
Number of trading days prior to conversion | tradingDay | 3 | |||
Transaction costs | $ 3.8 | |||
Transaction related costs | $ 0.3 |
Deferred Policy Acquisition C_3
Deferred Policy Acquisition Costs, Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Deferred Policy Acquisition Costs Disclosures [Abstract] | |||
Deferred policy acquisition costs | $ 11,655 | $ 11,533 | |
Deferred ceding commission | (181) | (114) | |
Accumulated amortization | (10,270) | (9,986) | |
Deferred policy acquisition costs, net | 1,204 | $ 1,433 | |
Total amortization expense | $ 300 | $ 400 |
Loss and Loss Adjustment Expe_3
Loss and Loss Adjustment Expense Reserves (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] | ||
Balance at beginning of period | $ 73,438 | $ 57,093 |
Less reinsurance recoverable | 0 | (33,941) |
Net balance at beginning of period | 73,438 | 23,152 |
Incurred related to: | ||
Total incurred | 22,060 | 12,263 |
Paid related to: | ||
Current year | 8,035 | 695 |
Prior years | 14,865 | (18,200) |
Total paid | 22,900 | (17,505) |
Net balance at end of period | 72,508 | 52,887 |
Plus reinsurance recoverable | (4,408) | (8,694) |
Balance at end of period | 76,916 | 61,581 |
Property, Liability and Casualty Insurance Product Line | ||
Incurred related to: | ||
Current year | 21,874 | 9,566 |
Prior years | 96 | 2,664 |
Total incurred | $ 21,970 | $ 12,230 |
Reinsurance - Narrative (Detail
Reinsurance - Narrative (Details) | Jan. 01, 2022 |
Reinsurance Disclosures [Abstract] | |
Reinsurance ceding rate | 30.00% |
Reinsurance - Schedule of reins
Reinsurance - Schedule of reinsurance (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Effects of Reinsurance [Line Items] | |||||
Total premiums earned | $ 28,131 | $ 25,822 | |||
Direct Unearned Premium | 16,924 | $ 15,726 | |||
Ceded Unearned Premium | (359) | 0 | |||
Ceded Loss and LAE Reserves | (4,408) | $ (8,694) | 0 | $ (33,941) | |
Net Premium Written | 20,530 | $ 91,308 | |||
Net Premium Earned | 19,691 | 77,983 | |||
Net Unearned Premium | 16,565 | 15,726 | |||
Net Losses and LAE Incurred | 21,970 | 88,290 | |||
Net Loss and LAE Reserves | 72,508 | 73,438 | |||
Direct | |||||
Effects of Reinsurance [Line Items] | |||||
Direct Premium Written | 29,328 | 110,719 | |||
Total premiums earned | 28,131 | 111,063 | |||
Direct Unearned Premium | 16,924 | 15,726 | |||
Direct Losses and LAE Incurred | 29,072 | 102,991 | |||
Direct Loss and LAE Reserves | 76,916 | 73,438 | |||
Ceded | |||||
Effects of Reinsurance [Line Items] | |||||
Ceded Premium Written | (8,798) | (19,411) | |||
Ceded Premium Earned | (8,440) | (33,080) | |||
Ceded Unearned Premium | (359) | 0 | |||
Ceded Losses and LAE Incurred | (7,102) | $ (14,701) | |||
Ceded Loss and LAE Reserves | $ (4,408) | $ 0 |
Leases, Commitments, and Cont_2
Leases, Commitments, and Contingencies (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2022USD ($)stockholderlocation | |
Commitments and Contingencies Disclosure [Abstract] | |
Number of real estate locations | location | 2 |
Right-of-use asset | $ 13.8 |
Right-of-use assets, statement of financial position, extensible enumeration | Prepaid expenses and other assets |
Operating lease liability | $ 18.4 |
Operating lease liability, statement of financial position, extensible enumeration | Other liabilities |
Weighted average remaining operating lease term (in years) | 7 years 3 months 18 days |
Weighted average discount rate | 510.00% |
Number of stockholders that commenced litigation | stockholder | 1 |
Stockholders_ Equity (Details)
Stockholders’ Equity (Details) - shares | Mar. 31, 2022 | Dec. 31, 2021 |
Stockholders' Equity Note [Abstract] | ||
Common stock, shares authorized (in shares) | 640,000,000 | 640,000,000 |
Common stock, shares outstanding (in shares) | 130,183,262 | 128,221,885 |
Common stock, shares issued (in shares) | 130,183,262 | 128,221,885 |
Convertible preferred stock, shares authorized (in shares) | 10,000,000 | |
Convertible preferred stock, shares outstanding (in shares) | 0 |
Public and Private Warrants (De
Public and Private Warrants (Details) | 3 Months Ended |
Mar. 31, 2022tradingDay$ / sharesshares | |
Public and Private Warrants (Details) [Line Items] | |
Number of shares to purchase (in shares) | shares | 1 |
Share price per share (in dollars per share) | $ / shares | $ 11.50 |
Purchase period, after completion of business combination | 30 days |
Purchase period, after IPO closing date | 12 months |
Period prior written notice of redemption | 30 days |
Closing period (in dollars per share) | $ / shares | $ 18 |
Trading days | tradingDay | 20 |
Threshold trading day period | 30 days |
Expiration period | 5 years |
Public Warrants | |
Public and Private Warrants (Details) [Line Items] | |
Number of warrants outstanding (in shares) | shares | 7,666,646 |
Private Warrants | |
Public and Private Warrants (Details) [Line Items] | |
Number of warrants outstanding (in shares) | shares | 180,000 |
Warrant | |
Public and Private Warrants (Details) [Line Items] | |
Price per warrant (in dollars per share) | $ / shares | $ 0.01 |
Stock Option Plans - Narrative
Stock Option Plans - Narrative (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share based compensation expense | $ 5,000,000 | ||
Total unrecognized compensation cost | $ 48,300,000 | ||
Recognized average period | 2 years 6 months 18 days | ||
Total grant date fair value of shares vested | $ 5,000,000 | ||
Issued outstanding performance-based awards (in shares) | 150,000 | ||
Awards issued (in shares) | 819,227 | ||
PSUs term | 5 years | ||
Expense from PSUs | $ 100,000 | ||
Expected dividend yield | 0.00% | ||
Unrecognized stock-based compensation cost | $ 1,200,000 | ||
Stock Plan 2021 | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Restricted stock units granted (in shares) | 819,227 | ||
Recognized average period | 1 year 11 months 12 days | ||
Performance Based Awards | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total unrecognized compensation cost | $ 0 | ||
Stock-based compensation expense | $ 2,500,000 | ||
Awards issued (in shares) | 2,216,870 | ||
Vesting threshold trading days | 20 days | ||
Trading window | 30 days | ||
Performance Based Awards | Specific Number Of Policies In Force | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | 33.30% | ||
Performance Based Awards | Positive Operating Cash Flow For At Least One Financial Quarter | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | 33.30% | ||
Performance Based Awards | Specific Price Per Share Over Time Period | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | 33.30% | ||
Stock Plan 2021 | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Common stock reserved for issuance (in shares) | 38,018,247 | ||
Vesting period | 4 years | ||
Expected dividend yield | 0.00% |
Stock Option Plans - Schedule o
Stock Option Plans - Schedule of restricted stock units (Details) | 3 Months Ended |
Mar. 31, 2022$ / sharesshares | |
Number of RSUs | |
Beginning balance (in shares) | shares | 7,241,980 |
Granted (in shares) | shares | 819,227 |
Vested (in shares) | shares | (496,366) |
Forfeited (in shares) | shares | (620,551) |
Ending balance (in shares) | shares | 6,944,290 |
Weighted-Average Fair Value | |
Beginning balance (in dollars per share) | $ / shares | $ 8.19 |
Granted (in dollars per share) | $ / shares | 1.28 |
Vested (in dollars per share) | $ / shares | 10.15 |
Forfeited (in dollars per share) | $ / shares | 6.03 |
Ending balance (in dollars per share) | $ / shares | $ 7.43 |
Stock Option Plans - Schedule_2
Stock Option Plans - Schedule of estimate the value of options granted (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Forfeiture rate | 26.20% |
Volatility | 62.00% |
Expected term (years) | 5 years 3 months 29 days |
Risk-free interest rate | 0.53% |
Expected dividends | 0.00% |
Stock Option Plans - Schedule_3
Stock Option Plans - Schedule of activity of stock option plan (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | |
Mar. 31, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Stock Number of Options | |||
Beginning balance (in shares) | 2,374,504 | ||
Options granted (in shares) | 0 | ||
Options exercised (in shares) | 0 | ||
Options cancelled or expired and returned to plan (in shares) | (717,331) | ||
Ending balance (in shares) | 1,657,173 | ||
Vested and exercisable to vest (in shares) | 723,575 | ||
Vested and expected (in shares) | 1,440,785 | ||
Weighted- Average Exercise Price | |||
Beginning balance (in dollars per share) | $ 3 | ||
Options granted (in dollars per share) | 0 | ||
Options exercised (in dollars per share) | 0 | ||
Options cancelled or expired and returned to plan (in dollars per share) | 3 | ||
Ending balance (in dollars per share) | 3.01 | ||
Vested and exercisable to vest (in dollars per share) | 2.98 | ||
Vested and expected (in dollars per share) | $ 3 | ||
Weighted- Average Remaining Contractual Term (Years) | |||
Outstanding | 7 years 11 months 8 days | 8 years 3 months | |
Vested and exercisable to vest | 7 years 8 months 15 days | ||
Vested and expected | 7 years 10 months 24 days | ||
Aggregate Intrinsic Value (in thousands) | |||
Outstanding | $ 0 | $ 375 | |
Vested and exercisable to vest | 0 | ||
Vested and expected | $ 0 |
Stock Option Plans - Schedule_4
Stock Option Plans - Schedule of stock-based compensation expense for employee and nonemployee options (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation | $ 5,258 | $ 3,208 |
Cost of revenues | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation | 304 | 41 |
Research and development | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation | 883 | 226 |
Sales and marketing | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation | 344 | 17 |
Other operating expenses | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation | $ 3,727 | $ 2,924 |
Income Taxes (Details)
Income Taxes (Details) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | ||
Effective tax rate | 0.00% | 0.00% |
Segment and Geographic Inform_3
Segment and Geographic Information - Narrative (Details) | 3 Months Ended |
Mar. 31, 2022segment | |
Segment Reporting [Abstract] | |
Number of operating segment | 2 |
Segment and Geographic Inform_4
Segment and Geographic Information - Schedule of operating results (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total revenue | $ 20,699 | $ 17,276 |
Total contribution | (5,532) | (2,595) |
Insurance services | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total revenue | 19,503 | 16,228 |
Total contribution | (4,419) | (1,863) |
Enterprise business solutions | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total revenue | 1,196 | 1,048 |
Total contribution | $ (1,113) | $ (732) |
Segment and Geographic Inform_5
Segment and Geographic Information - Schedule of contribution to its total loss from operations (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Segment Reporting [Abstract] | ||
Total segment contribution | $ (5,532) | $ (2,595) |
Ceded premium, losses and LAE | 1,293 | (2,905) |
Other income | 522 | 1,147 |
Policy services expenses and other | 1,606 | 371 |
Sales, marketing, and other acquisition costs | 6,340 | 47,167 |
Research and development | 2,351 | 2,006 |
Amortization of capitalized software | 3,368 | 2,651 |
Other operating expenses | 13,438 | 8,582 |
Loss from operations | (34,450) | (61,614) |
Total other expense | (131) | 42,013 |
Loss before taxes | $ (34,319) | $ (103,627) |
Segment and Geographic Inform_6
Segment and Geographic Information - Schedule of geographical breakdown of direct earned premiums (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | $ 28,131 | $ 25,822 |
California | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 15,760 | 15,146 |
Washington | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 3,585 | 2,985 |
New Jersey | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 2,682 | 2,459 |
Oregon | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 1,816 | 1,796 |
Illinois | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 1,138 | 1,041 |
Arizona | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 1,759 | 1,268 |
Pennsylvania | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | 635 | 657 |
Virginia | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Total premiums earned | $ 756 | $ 470 |
Net Loss per Share - Narrative
Net Loss per Share - Narrative (Details) | Feb. 28, 2021shares |
Earnings Per Share [Abstract] | |
Reverse recapitalization ratio | 1.01547844 |
Net Loss per Share - Schedule o
Net Loss per Share - Schedule of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Numerator: | ||
Net loss attributable to common stockholders ($ in thousands) | $ (34,319) | $ (103,627) |
Denominator: | ||
Weighted average common shares outstanding — basic (in shares) | 128,715,031 | 75,791,557 |
Weighted average common shares outstanding - diluted (in shares) | 128,715,031 | 75,791,557 |
Net loss per share attributable to common stockholders — basic (in dollars per share) | $ (0.27) | $ (1.37) |
Net loss per share attributable to common stockholders - diluted (in dollars per share) | $ (0.27) | $ (1.37) |
Net Loss per Share - Schedule_2
Net Loss per Share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total anti-dilutive securities (in shares) | 18,665,000 | 12,450,624 |
Convertible preferred stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total anti-dilutive securities (in shares) | 0 | 0 |
Outstanding stock options - Stock Plan | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total anti-dilutive securities (in shares) | 1,657,173 | 4,595,624 |
Warrant | Warrants for preferred stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total anti-dilutive securities (in shares) | 0 | 0 |
Warrant | Warrants for common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total anti-dilutive securities (in shares) | 7,846,667 | 7,846,667 |
Restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total anti-dilutive securities (in shares) | 9,161,160 | 8,333 |
Related-Party Transactions (Det
Related-Party Transactions (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | |||
Apr. 30, 2020 | Aug. 31, 2014 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Chief Executive Officer | Related Party Loan Receivable | |||||
Related-Party Transactions (Details) [Line Items] | |||||
Loan amount | $ 0.4 | ||||
Related party rate | 1.50% | 3.09% | |||
Period after termination of employment | 1 year | ||||
Period after issuance | 10 years | ||||
Investors | |||||
Related-Party Transactions (Details) [Line Items] | |||||
Revenue from related parties | $ 1 | $ 1 | |||
Accounts receivable | $ 1.5 | $ 0 |
Business Disposition (Details)
Business Disposition (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Assets | ||
Total assets | $ 9,253 | $ 0 |
Liabilities | ||
Liabilities held for sale | 6,156 | $ 0 |
Disposal Group, Held-for-sale, Not Discontinued Operations | Enterprise business solutions | ||
Assets | ||
Cash and cash equivalents | 2,393 | |
Prepaid expenses and other assets | 1,705 | |
Website and software development costs, net | 5,155 | |
Total assets | 9,253 | |
Liabilities | ||
Deferred revenue | 5,906 | |
Accounts payable and accrued expenses | 250 | |
Liabilities held for sale | $ 6,156 |